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Chapter I
Introduction

1

Ceftriaxone (CRO)

is the first clinically useful

cephalosporin to exhibit a sufficiently long half-life (t1/2, (3
phase) such that once a day treatment is practical for most
infections (1-3). This long half-life is exhibited principally

because the total body clearance (the sum of the renal and
biliary clearance) of this compound is much lower than those of

other drugs in this group (4). A second major advantage
demonstrated by CRO is that it typically exhibits remarkably

stable pharmacokinetic behavior (e.g., stable half-life) even in
the presence of severe renal (5) or hepatic failure (6). The only

significant exception to this observation is that its half-life
and non-renal

(i.e., biliary) clearance appear to be distributed

bimodally in renal failure cases with 85% of subjects exhibiting

a mean half-life of about 12 hr (~1.5 times that seen in normal
healthy volunteers) and the remaining 15% of subjects exhibiting

a half-life of about 30 hr (5). That is, the ability of this
minority of renal failure patients to eliminate CRO via biliary
excretion is significantly compromised and this results in

excessive drug accumulation unless dosage is adjusted

appropriately. Therefore, a principal goal of the series of
studies included in this dissertation was to attempt to establish
an animal model of this disease-drug interaction. This effort was

focused on the development of a rat model because it is difficult
to identify the causative mechanisms for such phenomena in

patients.
Beyond developing a suitable animal model,

2

it was also

necessary to validate and develop analytical methods to determine

CRO concentration in biological fluids (serum, urine, bile,

etc.). Thus, in Chapter II, the results of various efforts to
establish assay methods or modify available procedures which

would fulfill this need are described. Serum samples were

analyzed for their CRO content using the HPLC methods developed

by Kwon et al. or modifications thereof (7, 8). However, bile and
urine are much more complicated body fluids because they

contained numerous endogenous substances which interfered with

the CRO assay developed by Kwon et al.

(7, 8). Other available

assays for the quantitation of CRO in urine and bile from other
species (man and dog), did not provide adequate resolution of CRO
from endogenous compounds in rat urine and bile (9,

10). Finally,

efforts were made to modify the HPLC method of Ascalone and Dal
Bo (11). This procedure employs normal phase HPLC for the
separation of CRO from endogenous compounds in urine but without

an internal standard. Substantially through good fortune a

suitable internal standard was identified and used to develop an
assay adequate for the studies which were planned.
The studies to be undertaken first required the

identification and development of a suitable animal model.
Available data suggested that the rat would be appropriate. For

example, rats excrete a large fraction (-50%) of a dose of CRO as
unchanged drug in bile in the first 8 hr following bolus

administration (12) . Furthermore, the urinary and fecal recovery
studies of Kwon et al.

(8)

support the finding of Fukazawa and

3

coworkers (12). Thus, the quantitative significance of biliary

and renal clearance pathways is similar in man and rat (8,

12).

Another desirable feature of this model system is that the extent

of CRO plasma protein binding in humans and rats has been
reported to be similar and both species exhibit an increase in

free fraction as drug concentration increases (1, 8,

13).

Moreover, the biliary excretion of many compounds has been

extensively studied in the rat and it has been shown that this
species exhibits many similarities to man in the biliary handling

of drugs (14,

15). Finally, there are several well studied models

of renal failure in the rat (16). Of the available methods for

producing renal failure in rats, uranyl nitrate (UN)

perhaps the simplest and most reproducible (16).

injection is

Furthermore, the

mechanisms by which UN causes renal failure are well understood
(17-20). Thus, this method was adopted in this investigation.

Collectively, since the available data suggest that the rat
could be exploited as an appropriate model for the diminished

biliary clearance of CRO in man, we proposed to perform a

comprehensive series of studies to evaluate CRO pharmacokinetics
in this species.

1. Development of a Rat Model to Study Biliary Clearance in
Severe Renal Failure: Preliminary Study of Ceftriaxone Clearance
in Rats with Renal Failure and Controls (Chapter III)
The initial studies were performed to determine the optimal
dose and route of UN administration and to assess the

reproducibility of UN induced renal failure. These studies were

4

also performed to determine if the cannulation of the femoral

artery,

femoral vein, bile duct, and duodenum was a viable

surgical procedure for studying pharmacokinetics of CRO in
healthy rats and those with renal failure.

2. Comprehensive Evaluation of the Uranyl Nitrate Induced Renal
Failure Model on the Pharmacokinetics of Ceftriaxone in the Rat
(Chapter IV)

After the completion of initial experiments on a small

number of rats, a comprehensive examination of the rat model of
renal dysfunction in a statistical relevant number of animals was

performed to assess the pattern of renal, biliary,

and total body

clearance of CRO and to provide supplementary data on the model

itself. Some factors that may impact the pharmacokinetics of this
drug,

including serum protein binding and the extensive surgical

preparation of the rat, were also examined.

3. Alterations of Ceftriaxone Biliary Clearance and Excretion by
a Model Bile Acid (Tauroursodeoxycholate)

in Healthy Rats and

Those with Uranyl Nitrate Induced Renal Failure (Chapter V)
In the last series of studies, attempts were made to

identify the mechanisms which modulate the biliary clearance of

CRO in healthy rats and those with renal failure.

Since the identity of the transport protein controlling the
biliary excretion of CRO has not been established and few studies
of biliary excretion in renal failure have been performed,

it

would be of interest to understand the factors which influence

biliary clearance of CRO. Our working hypotheses were :

5

(a) that

the renal failure subjects who exhibit the striking decrease in

non-renal

(i.e., biliary) clearance (with long half-life)

of CRO

do so because they are not capable of excreting appropriate

amounts of selected bile acids and hence the bile acid dependent
component of biliary excretion is decreased (as suggested by the

(21) and/or (b) that at least

normal volunteer data reported)

some endogenous compounds (perhaps including bilirubin and
selected bile salts such as deoxycholate at sufficiently high

concentrations) can compete with CRO for excretion into the bile.
In addition, it has been observed that there is a large

interindividual variation in the biliary clearance of CRO in
healthy humans (22) and that the excretion rate of bile acids is

significantly correlated with that of CRO in healthy human

subjects (r = 0.83, p < 0.05)

(21). Based on this knowledge, we

hypothesized that CRO and bile acids might have the same biliary
transport carrier system. Thus, tauroursodeoxycholate (TUDC) was
used in a series of studies as a model bile acid to investigate

the effect of this class of compounds on the biliary clearance of

CRO in the presence and absence of severe renal failure. TUDC was
an attractive choice principally because it rarely induces
hepatic abnormalities in the rat even at high doses (23), its

metabolic fate is well understood (24), its chemical structure is

similar to chenodeoxycholate (the most abundant natural bile acid
in human serum), and lastly,

its serum concentration can be

readily measured after dosing (25). The current controversy

regarding whether this bile acid shares the same biliary

6

transport system with CRO was another important reason for

choosing TUDC. Xia et al. suggested that this bile acid inhibits
the biliary excretion of CRO (26) while others contend that it

does not share the same biliary transport carrier with CRO (27).
In Chapter V, the consequences of TUDC on the biliary clearance
of CRO in normal and uremic rats were examined in detail. The
principal purpose of this series of studies was to determine the
impact of TUDC on the biliary transport rate of CRO, to

characterize selected features of the biliary canalicular
transport carrier for this drug in rats with or without renal
failure, and to compare the possible differences of such
transport systems in conscious intact rats in contrast with the

results from isolated perfused rat liver preparation (28).
Collectively, the battery of studies outlined in this
introduction should significantly improve our understanding of

the biliary clearance of CRO and might provide useful insight
into the factors causing the bimodal distribution of its non-

renal clearance in renal failure patients. Such insights might be
used to prevent the undesired accumulation of drug in such

patients and could provide insight into the pharmacokinetics of
other drugs being developed to treat bacterial infections which
are becoming an increase cause of morbidity and mortality (29,
30) .
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Chapter II

Determination of Ceftriaxone Concentrations in Serum, Bile,

and Urine Samples by High-performance Liquid Chromatography
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ABSTRACT
Development of analytical methods to determine ceftriaxone

(CRO) concentration in several biological fluids is critical for
studying pharmacokinetics of this drug in animals. High

specificity and sensitivity are required for assaying biological
samples. An ion-pair reversed phase HPLC method works well for
the determination of CRO in rat serum. However,

CRO in rat urine

and bile samples cannot be quantitated in our laboratory by the
above method nor other HPLC methods which we attempted to
replicate from the published reports of others. Ascalone and Dal

Bo reported a normal phase HPLC method for separation of CRO in
urine but without an internal standard. Therefore,

in the present

study, we modified Kwon's HPLC method for the determination of

CRO concentration in serum samples. In addition,

starting with

the method of Ascolone and Dal Bo, we also developed an improved
HPLC assay by discovering that fluorescein was a satisfactory

internal standard. This improved method allowed the quantitation
of CRO in rat urine and bile samples.
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INTRODUCTION

Development of analytical methods to determine ceftriaxone
(CRO) concentration in biological fluids is critical for studying

the pharmacokinetics of this drug in animals. Both high

specificity and sensitivity are required for assaying biological
sample. An ion-pair reversed phase HPLC method was described by
Kwon et al. and this method works well for the determination of

CRO in rat serum (1). However, CRO in rat urine and bile samples

could not be separated and quantitated by the above method or any
of a number of other methods which have been reported (2-5). The

fundamental difficulty with these procedures was that numerous
endogenous chemicals interfere (co-elute) with CRO. Ascalone and

Dal Bo reported a normal phase HPLC method for the quantitation

of CRO in urine but without internal standard (6).

Therefore, in the present study, we modified Kwon's HPLC

method for the determination of CRO concentration in serum sample
and evaluated the assay using coded unknown samples.

In addition,

based on the method of Ascalone and Dal Bo, we also developed a

HPLC assay using fluorescein as an internal standard.

MATERIALS AND METHODS
Chemicals and Reagents

Acetonitrile, HPLC grade, was from J. T. Baker
(Phillipsburg, NJ). Ammonium carbonate (analytical reagent grade)

was purchased from Aldrich Chemical Company (Milwaukee, WI).
Ethyl alcohol USP was ordered from AAPER Alcohol and Chemical Co.
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(Shelbyville, KY). Fluorescein (FR), cetrimide

(hexadecyltrimethylammonium bromide), and cephalothin (reagent
grade) were obtained from Sigma Chemical Co.

(St Louis, MO).

Analytical grade CRO was provided by Hoffmann-La Roche (Basel,
Switzerland) .

Chromatography System

The HPLC system used in these studies was equipped with a
Waters Model 510 pump (Waters Associates), a Model 441 absorbance

detector operating at a wavelength of 254 or 280 nm (Waters
Associates), and a WISP Model 710B sample processor (Waters
Associates). A Powermate SX Plus computer for the HPLC system

connected with a NEC Pinwriter P5200 printer was employed for
collecting the data, recording the chromatograms,

integrating the

peak area, and saving the acquired data. The MAXIMA 820

Chromatography Workstation (Waters Dynamic Solutions, Division of
MILLIPORE) was installed on the computer for automated data

acquisition and handling.
HPLC Assay of Serum Sample
The modified HPLC method of Kwon et al.

(1) was employed to

determine CRO serum concentration. Briefly, the CRO serum sample

(50 pl) was diluted with 50 pl of distilled water and
deproteinated with 150 pl of acetonitrile. Then, 200 pl of
cephalothin solution (25 pg/ml in water) was added as an internal

standard. The mixture was shaken for 30 seconds and centrifuged
for 15 minutes at 4500 r.p.m. at room temperature. The
supernatant (25 pl) was injected onto the HPLC system.
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The mobile phase consisted of acetonitrile:cetrimide
solution (10 g/1 in water): IM phosphate buffer (pH 7)zdistilled

water in a ratio of 42:30:1:27. The sample was resolved into its

components on a pBondapak C18 column (3.9 x 300 mm,

10 pm, Waters

Associates) with a flow rate of 1.5 ml/min. The eluent was

monitored at 254 nm.
HPLC System Maintenance after Serum Sample Assay

Ion-pair reversed phase HPLC has some practical limitations.
In the present method, the cetrimide and buffer salts of the
mobile phase could cause blockage of the pump or injector.

Furthermore, they could also be destructive to the packing
materials. Therefore, extreme care was taken to maintain the

integrity of the HPLC system because of the salt content of the
mobile phase used. In general, the entire HPLC system was flushed
with approximately 300 ml of mobile phase which consisted of
acetonitrile : water (42:58) after each run. Deposition of salts

was prevented by allowing the pump to run overnight at a flow

rate of 0.2 ml/min with this mobile phase.
HPLC Assay of Urine and Bile Samples

The HPLC assay for CRO in urine and bile samples was

developed by introducing an internal standard into the method of

Ascolone and Dal Bo (6). To be more specific, urine or bile
samples (50 pl) were diluted 22-fold and 28-fold, respectively,

with distilled water. The diluted sample (100 pl) was vigorously
mixed with 50 pl of fluorescein in acetonitrile (25 pg/ml for

urine sample and 35 pg/ml for bile sample). Acetonitrile (150 pl)
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was added to above solution. The mixture was centrifuged for 10

minutes at 4500 r.p.m. at room temperature and the supernatant
(25 pl for bile sample or 40 pl for urine sample) was injected
onto the HPLC system.

The eluent mixture contained acetonitrile :water : ammonium

carbonate solution (1%, w/v)

in a ratio of 75:21:4 with a flow

rate 1.7 ml/min. A Hibar type column filled with NH? bonded-phase
LiChrosorb was used (4 x 125 mm,

5 pm, Merck). The eluent was

monitored at 280 nm.
The HPLC System Maintenance after Bile and Urine Sample Assay
After each run, the entire system was flushed with a mobile
phase of acetonitrile-water (80:20, v/v) at a flow rate of 0.2

ml/min for at least 12 hours. Methanol-water (90:10, v/v) was
used to store the column during periods of non-use.

Calibration Curve and Linearity
For serum samples, the wired of the HPLC assay was examined

by preparing calibration curves in the range of 1.30-167 pg/ml.

The appropriate amount of CRO was added to blank rat serum to
yield final concentrations of 1.30, 2.50, 4.30, 8.40,
25.1, 41.8,

62.7, 83.5, 105,

125,

12.5,

16.7,

146, and 167 pg/ml. The samples

were processed and analyzed as described above. The calibration

curve was constructed by plotting the peak-area ratios

(CRO/internal standard) against the known concentrations of CRO.
For bile and urine samples, the ranges of calibration curves
were 10.5-1840 pg/ml and 9.20-1300 pg/ml, respectively. The

appropriate amount of CRO was added to blank rat bile or urine to
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give final concentrations of 10.5,
837,

31.4, 62.7,

126,

251, 502,

1260, and 1840 pq/ial in bile as well as 9.20, 36.6, 73.2,

146, 293, 418, 586, 795,

1050, and 1300 pq/ml in urine. The other

procedures were the same as described above.

Quality Control for Serum Sample Assay
Serum coded unknowns were made by the laboratory supervisor.
Three coded unknowns were assayed together with standard curve

samples and samples from the study with each analytical run. The
calculated CRO concentrations of the coded unknowns were reported

to the supervisor. If the observed concentrations of CRO from the
coded unknowns were not consistent with the spiked

concentrations, the assay was repeated until the estimate of the
concentration in the coded unknown was acceptable (average error

of 10% or less).

RESULTS

HPLC Assay of Serum Sample
Chromatograms of blank serum, serum spiked with CRO, and

serum from in vivo studies indicated that CRO was completely

resolved from the internal standard and there were no interfering
peaks (Figures la-lc).

HPLC Assay of Bile and Urine Samples

Chromatograms of bile and urine samples assayed on a normal

phase Hibar type column revealed two sharp peaks representing CRO

and its internal standard (Figures 2a-2c, Figures 3a-3c). The
application of a NH2 bonded-phase LiChrosorb column gave optimal
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resolution of CRO and fluorescein as well as resolved the
analytes from endogenous substances in bile and urine.

Calibration Curves

Good linearity between CRO concentrations and peak-area
ratios was observed over the concentration ranges of 1.50-200
//g/ml in serum, 10.5-1840 /Jg/ml in bile, and 9.20-1300 /Jg/ml in
urine (Figure 4-6). The coefficients of determination (r2) were

typically greater than 0.998 for all three curves. The linear

regression constants of standard curves assayed together with
urine or bile samples from CRO pharmacokinetic studies described

in Chapter IV are listed in Table 1. All ^-intercepts were close
to zero and slopes were similar between standard curves in bile

and urine.
Assay Quality Control
CRO concentration determined for the serum coded unknowns

was consistent with the spiked concentration made by the
laboratory supervisor. The percent error was calculated using the

equation:
Error% = 100x(c^^ - C^^)/C^^

The mean error of 32 coded unknowns (concentration > 5.7 /jg/ml)
assayed during the studies described in Chpaters IV and V was
4.7%

(Figure 7). Therefore, the assay technique used in this

study was at least adequate.

DISCUSSIONS

CRO is a highly polar compound which is very soluble in
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water. The retention of CRO could not be achieved on the

jUBondapak C18 reversed phase column even when water was used as a

mobile phase. Cetrimide is a lipophilic quaternary ammonium salt
which forms ion pairs with CRO. As a result, the retention of CRO
on a C18 column was greatly increased.

Normal phase HPLC assay was performed on a polar NH2 bondedphase LiChrosorb column for both urine and bile samples. The
polar alkylamino bonded phase served as a weak base to attract

this acidic drug.
As a highly polar and water-soluble compound, CRO cannot be

extracted from plasma by techniques such as a classical liquid

liquid extraction. Therefore, CRO serum samples were
deproteinated with acetonitrile and an aliquot of the supernatant

was directly injected onto the column without any further

purification. The purpose of using acetonitrile in bile and urine
samples was to precipitate some interfering endogenous

substances.
Finally, the chromatograms suggest that the columns used in
this study resolved CRO from interfering substances. The

calibration curves revealed that the methods developed in the
present study are suitable to determine the concentration of CRO
in rat serum, urine, and bile samples.
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Table 1. Linear Regression Constants for Standard Curve Samples

Assayed with Bile and Urine Specimens from CRO Pharmacokinetic

Studies Described in Chapter IV

Slope

Y-intercept

r2

(ml/pg)
Bile Samples

7/15/93

0.0425

0.0018

0.998

7/19/93

0.0165

0.0018

0.996

7/21/93

0.0087

0.0019

0.999

7/26/93

0.0788

0.0018

0.998

8/05/93

-0.0018

0.0019

0.999

8/06/93

-0.0178

0.0019

0.999

Urine Samples
8/12/93

-0.0109

0.0033

0.999

8/17/93

-0.0498

0.0070

0.993

8/18/93

0.0939

0.0062

0.999

8/20/93

-0.0245

0.0060

1.00

8/25/93

-0.0058

0.0058

0.998
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Figure 1.

(a). Representative chromatogram of blank serum,

(b).

Representative chromatogram of a spiked serum sample (CRO

concentration = 104 pg/ml).

(c). Representative chromatogram of a

serum sample from an in vivo study (CRO concentration = 41.1

pg/ml). Peaks:

1 = internal standard; 2 = CRO.
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Figure 2.

(a). Representative chromatogram of blank bile.

(b).

Representative chromatogram of a spiked bile sample (CRO

concentration = 502 pg/ml).

(c). Representative chromatogram of a

bile sample from an in vivo study (CRO concentration = 1500 pg/ml) .

Peaks :

1 - internal standard ; 2 = CRO.
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Figure 3.

(a). Representative chromatogram of blank urine,

(b).

Representative chromatogram of a spiked urine sample (CRO

concentration = 73.2 /Jg/ml) .

(c) . Representative chromatogram of

a urine sample from an in vivo study (CRO concentration = 239

fjg/ml) . Peaks:

1 = internal standard ; 2 = CRO.
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Figure 4.

Calibration curve for CRO in serum samples over the

concentration range of 1.30-167 pg/ml. r2 > 0.999; Y-intercept
= -0.0087; slope = 0.0136 (ml//LZg) . IS = internal standard.
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Figure 5.

Calibration curve for CRO in urine samples over the

concentration range of 9.2 0-1300 /Jg/ml. r2 = 0.999 ; Y-intercept =
0.0201 ; slope = 0.0037 (ml/^g). IS = internal standard.
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Figure 6.

Calibration curve for CRO in bile samples over the

concentration range of 10.5-1840 /LZg/ml. r2 = 0.999; Y-intercept =

0.0065; slope = 0.0036 (ml//lg) . IS = internal standard.
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Chapter III

Development of a Rat Model to Study Biliary Clearance in
Severe Renal Failure: Preliminary Study of Ceftriaxone

Clearance in Rats with Renal Failure and Controls

42

Table of Abbreviation

CL^/ = biliary clearance of total drug
CL&/ = biliary clearance of free drug

CL^ = renal clearance of total drug
CLrf = renal clearance of free drug

CLsf = systemic clearance of total drug
CLsf = systemic clearance of free drug

f = free fraction of CRO in serum
UN = uranyl nitrate

Vdt = apparent volume of distribution of total drug, /3 phase
t1/2 = half-life, /3 phase
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ABSTRACT
An acute renal dysfunction model based on the injection of

uranyl nitrate (UN) was developed in male Sprague-Dawley rats and
ceftriaxone (CRO) pharmacokinetics was examined using this model.

Rats pretreated with UN exhibited a dramatic increase of serum
urea nitrogen concentration. Furthermore, as would be

anticipated, UN pretreatment significantly diminished the renal

clearance of total CRO (CLrt)

from 0.31 ml/min in the control

rats to 0.01 ml/min in the UN treated rats. It was also observed

that the biliary clearance of total drug (CL^) was increased
from 0.26 to 0.43 ml/min. In addition, total systemic clearance

(CLg1) , half-life (t1/2) , and volume of distribution (Vdt) of CRO
did not significantly change in the UN treated rats. Finally, the

serum protein binding of this drug was concentration-dependent
and decreased significantly as concentration of total drug

increased. These initial findings suggest that the rat model of

renal failure which we have developed exhibited several
characteristics similar to those observed in humans with severe

renal dysfunction. Hence, this model may be useful for the study
of CRO disposition in renal failure.
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INTRODUCTION
Renal dysfunction has strikingly different effects on the

pharmacokinetic characteristics of ceftriaxone (CRO)

in patients

with renal failure and these differences do not appear to be
associated with change in indices of renal function such as serum
creatinine or blood urea nitrogen. Specifically,

in clinical

studies, the majority of patients with severe renal failure have

only slightly increased half-lives (12 hr) of CRO (compared to ~8
hr in normal subjects). However, a small subset of patients

exhibit strikingly prolonged half-lives (-30 hr)

(1). The reduced

ability of this minority of renal failure patients to eliminate
CRO via biliary excretion should presumably cause accumulation of
this drug. Since exploration of the causative mechanisms in

patients may be limited by ethical and practical considerations,

it was necessary to perform studies on animals with experimental

renal failure. There are several available methods for producing
renal failure in rats. Among them, uranyl nitrate (UN)

injection

is probably the simplest and most reproducible (2-6). Therefore,
it was adopted in the present investigation.

The principal goal of this preliminary study was to
determine (i) whether UN consistently induced renal failure in
rats and (ii) whether cannulation of the bile duct, duodenum and
femoral artery produced a viable preparation for studying the

biliary and renal clearance of CRO in healthy rats and those with
renal failure.
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MATERIALS AND METHODS

Materials
Analytical grade CRO was provided by Hoffmann-La Roche Inc.

(Basel, Switzerland). Rocephin* (lot#0387) was used for
administration to the rats. Uranyl nitrate hexahydrate was
purchased from Fluka Chemie AG (Buchs, Switzerland) . Tygon
microbore tubing (formulation S-54-HL,

0.015 in. ID x 0.030 in.

OD x 0.075 in. wall) was obtained from Norton Performance
Plastics Co.

(Akron, OH) and polyethylene tubing (PE-60, 0.030

in. ID x 0.048 in. OD ) was ordered from the Clay Adams Division
of Becton Dickinson and Company (Parsippany, NJ). Silastic
medical-grade tubing (0.025 in. ID x 0.047 in. OD) was from Dow
Corning Corporation (Midland, Michigan). All other chemicals were

of reagent grade or the best grade commercially available.

Animals
Male Sprague-Dawley rats (300-325 g) were purchased from

Harlan Sprague Dawley Inc.

(Indianapolis, IN) and maintained

on a 12 hr light/dark cycle with free access to food and
water. The research protocol and animal usage in these studies
were approved by the West Virginia University Animal Care and Use

Committee.

Surgical Procedures
In this study, ether was selected as an anesthetic during

surgical procedures because of its rapid elimination in the body.
The duodenal catheter was prepared by using polyethylene tubing
(PE-60) with one side attached with an approximately 2 cm
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Silastic medical-grade tubing, which was soft and suitable to be
inserted into the duodenum. The catheters inserted into the bile

duct and femoral artery were made of Tygon microbore tubing.
Approximately 20 rats were used to develop the procedures needed
to simultaneously cannulate the femoral artery, bile duct, and
duodenum. Based on these studies, the standard surgical
procedures were established.

Rats were anesthetized with ether before surgery. To implant

bile duct and duodenal cannulas, a 2 cm midline incision was made
in the skin as well as underlying muscle of the abdomen. The

intestines were gently pushed aside with sterile gauze to allow
visualization of the common bile duct and duodenum. A catheter
was inserted into the common bile duct in the direction of the

liver while the other side of the bile duct was ligated. The
duodenal catheter was implanted into the duodenum near its
junction with the bile duct. Both catheters were tunneled
subcutaneously and exteriorized at the back of the neck, secured
with a suture, and connected to each other for near normal bile

circulation until the initiation of the CRO pharmacokinetic

study. When the pharmacokinetic study of CRO was initiated, the
bile duct cannula was disconnected from the duodenal cannula for
the collection of bile samples. The abdominal muscle was closed
with sterile sutures while the skin was closed with sterile

staples. In addition, a Tygon catheter was inserted into the left

femoral artery for CRO administration and blood sampling. This
catheter was sutured to the adjacent tissue and tunneled
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subcutaneously to the back of the neck where it was secured. This

arterial cannula was filled with sterile saline containing
heparin (100 u/ml) to maintain patency and was plugged using a T-

pin. After this surgery, the rats were allowed approximately 2 4

hours to recover before the initiation of the CRO pharmacokinetic
study.
UN Injection for Producing Acute Renal Failure in Rats
Several methods are available for producing renal

dysfunction in experimental animals. They include the

administration of various nephrotoxic agents (such as dichromate,
UN, and glycerol), temporary occlusion of the renal artery,

intrarenal infusion of vasoconstrictors, ureteral ligation, and

partial nephrectomy. Since the relative importance of the
pathophysiological components of acute renal failure in patients

can be complicated (7), it may be difficult to determine which
experimental method for producing renal failure in animals yields

results that are most representative of the clinical condition.
However, the renal failure induced in the laboratory animals for

pharmacokinetic investigations should fulfill the following
criteria : easy to induce, predictable in outcome, high survival
rate, and close resemblance to the

clinical/biochemical/histologic picture of acute renal failure in
man. Based on the above criteria, UN injection (s.c.) was

selected as the method to induce renal failure. Approximately 20
rats were used in pilot studies to select a dose and route for UN

administration. Ultimately, a dose of 10 mg/kg, as a 10 mg/ml
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solution in sterile saline given by the subcutaneously route was
selected (8). Control animals were surgically prepared just as

the UN animals were and they were injected with saline instead of

the UN solution described above.
Animal Treatment
In the present study, rats were divided into two populations
with six in the UN Treated Group (UN Group)

and six in the

Control Group. All rats received the surgical treatment described
above to implant the femoral artery, bile duct, and duodenal

cannulas.
On day 0, blank blood samples were obtained from all rats by

tail vein puncture. UN (10 mg/kg)

in physiological saline

solution (10 mg/ml) was administered subcutaneously to the rats

of the UN Group at the beginning of day 1. An egual volume of

saline solution was given by the same route of administration to
the control rats. Rats had free access to food and water through
out this time period. Two days later, all rats were surgically

prepared and then fasted overnight following the surgery but
water was provided ad libitum. CRO was dissolved in saline and
diluted to a final concentration of 20 mg/ml less than one hour
prior to dosing. All groups of rats received a single dose of CRO

(20 mg/kg, i.v. bolus) at the beginning of day 4 through the
indwelling cannula in the femoral artery and this catheter was

thoroughly rinsed with sterile saline to prevent sample
contamination.
The blood sampling schedule was pre-dose as well as 10, 30,
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75,

120, 180, 240, 360, and 480 minutes after the administration

of CRO. The volume of each sample was 300 pl. Bile samples were

collected pre-dose as well as over the intervals 0-30, 31-75, 76
120,

121-360, and 361-480 minutes post dosing. The volume of each

collection was recorded. Urine excreted during this 480 minute
experiment was collected using a standard plexiglass metabolic

cage and mixed with urine obtained from the urinary bladder from
each rat at the end of the experiment. The volume of total urine

was recorded and aliquots were saved. At the end of the

experiment and before sacrificing each rat a large volume of

blood (4 ml) was taken for serum protein binding studies. Serum
was separated from blood by centrifugation. All serum, bile, and

urine samples were stored at -20°C until used. The hematocrit was
measured for each rat on day 0 and immediately before CRO

administration (day 3).
Assays
CRO concentrations in serum, bile, and urine samples were

determined by previously established HPLC methods (see Chapter
II). The albumin and urea nitrogen levels were measured for all
blank serum samples using commercially available assay kits

(Sigma Diagonostics* BCP Albumin and Urea Nitrogen,

Sigma

Chemical Co.).
Pilot Study of In Vitro Protein Binding of CRO in Pooled Serum from

Normal Rats

Blank blood was obtained from 6 normal rats by aortic stick.
Serum was separated from blood by centrifugation. Pooled serum
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was spiked with CRO to various concentrations (20, 60,

200,

100,

150,

300, 400, 500, 650, and 800 gg/ml). The pH of serum (1 ml)

was measured and adjusted to 7.40 ± 0.05. The serum was

immediately transferred to an ultrafiltration device (Amicon
Centrifree Micropartition system, Amicon Division, W. R. Grace &

Co., Danvers, MA) and centrifuged at 1,250 g for 10 minutes at

25°C. The filtrate was analyzed to determine the concentration of
free CRO by using the HPLC method described in Chapter II.
In Vitro Protein Binding of CRO in Serum from Each Individual UN

Treated or Control Rat
Serum (1 ml)

from each rat was spiked with CRO to a

concentration of approximately 100 pg/ml. The remainder of the
procedure for the estimation of free fraction was the same as
described above.

Pharmacokinetic Parameter Estimates of CRO Using PCNONLIN
The serum concentration-time data from each rat were fitted

using PCNONLIN (SCI Software Company, Lexington, KT) to the
equation:
C = A e‘at + B e"pt
where A and B are the coefficients of the biexponential equation

while a and p are the relevant macro rate constants. The area
under drug concentration-time curve (AUC0.480 min or AUC0.J was
calculated according to the linear trapezoidal method. The

various clearances, t1/2 and Vdt of CRO were estimated for
individual rat using the following equations :

CL/ = (Total Amount of CRO in Urine) 0.480 mjn / AUC0.480 min
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CLb/ = (Total Amount of CRO in Bile) 0.480 mjn / AUC0.480 min

CL/ = Dose /

AUCq..

CL/ = CL//f

CV = CLb//f
CL/ = CL//f

t,,2 = 0.693//3
V/ = CL//2

Statistical Analysis
All data were reported as the mean ± one standard deviation.

The null hypothesis (Ho) proposed for all the comparisons was
that there would be no differences observed among sample means

for all dependent measures. The null hypothesis was tested by

using analysis of variance. JMP computer software (SAS Institute
Inc., Cary, NC) was used for the statistical analysis. An alpha

level of 0.05 was selected.

RESULTS

The Effects of UN Treatment and Surgical Preparation on Rats
The similar reduction of body weight in each group (~3%)
suggests that UN treatment had little effect on the body weight

of rats and this small decrease was probably due to the

combination of fasting and surgical trauma (Table 1).

The serum

urea nitrogen concentration which we measured and renal clearance

of CRO which we estimated should indicate whether renal

dysfunction was induced. Thus the dramatic enhancement (8-fold)
of serum urea nitrogen concentration which was observed in the UN
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treated rats (while the controls exhibited only a small variable
increase)

suggested that the protocol used in these studies was

satisfactory (Table 2). Serum albumin concentrations were reduced
significantly in the Control Group as well as UN treated rats and

the decrease was similar in the two groups (Table 1). This again

could be attributed to surgical trauma and fasting.
Mass Balance Data

Only 0.7% of the CRO dose was excreted in the urine of UN
treated rats (Table 3). In contrast, 47.1% of the dose was
recovered in the urine of control rats. The biliary recovery of

CRO in the UN treated rats was 77.7% compared to 56.4% in the
Control rats. The total recovery of CRO in the UN treated rats

was significantly smaller than that observed in their controls.
Pharmacokinetics of CRO

The log serum concentrations of total CRO appeared to
decline biexponentially with time and the two groups exhibited

similar profiles (Figure 1). The pharmacokinetic parameter
estimates derived from the concentration of total CRO are
presented in Table 4. The CL/ in rats with renal failure

approached zero but was approximately 0.31 ml/min in controls.

Although not statistically significant, there was a trend toward
an increase in CL^/ and v/ in rats with renal dysfunction.

Furthermore, the CL/ and t1/2 of CRO in rats with renal failure
were not significantly altered.
Protein Binding of CRO in Rat Serum
Serum protein binding of CRO was concentration-dependent
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with lower binding at higher concentrations of total CRO (Table

5). The change of % free CRO was relatively small when the total
concentration was below 100 pg/ml. However, the free fraction

increased strikingly at a total concentration of more than 100

^g/ml.
Free fraction of CRO was much greater in the Control Group
than in the pooled rat serum (both at 100 /Jg/ml) . We do not have

a satisfactory explanation of this behavior. However, since serum
was available from only 3 rats in the control group (see Table

6),

it is not unreasonable to ascribe this observation to

experimental error or possible faulty storage which was not
detected (see Appendix A).

DISCUSSION
The 8-fold increase in the serum urea nitrogen concentration

in the UN treated rats demonstrated that renal dysfunction was
successfully induced in these rats. It is noteworthy that this

parameter increased slightly in the control rats but was still

within the normal range. This later observation suggests that the
overnight fast and extensive surgery which these animals received

slightly altered the generation of urea nitrogen even in the

absence of UN treatment. The mechanisms responsible for the renal
failure observed in the UN treated rats have been extensively

studied (2-6). UN exerts its major action on the kidney at the

surface membranes of renal epithelial cells and the uranyl cation
complexes with phosphoryl, carboxyl, and sulfhydryl groups of
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surface membranes in a reversible fashion (9, 10). Subsequently,

UN further leads to the tubular necrosis, which results in the
obstruction,

ischemia, and backleakage of filtrate. As a result,

a decreased GFR and a strikingly increased serum urea nitrogen
concentration were observed. Furthermore, available evidence
suggests that UN is not a hepatotoxin and the reported data shows
that it does not change SGPT level (an index of hepatic function)

(6). The serum albumin level was similarly reduced in both

groups. The observation that both groups exhibited substantially

decreased serum albumin levels suggests that surgical trauma
caused this decrease. This explanation is consistent with those
reported in patients who have undergone extensive surgery (11).

With regard to the protein binding of CRO in rats,

it is

noteworthy that its concentration dependence resembles that seen
in humans (when the concentration of total drug was under 200

pg/ml)

(12). The protein binding behavior of CRO was not explored

in pooled uremic serum during this preliminary study. However, in
order to interpret the pharmacokinetic behavior of CRO in uremic
rats,

it is clear that future studies must include a complete

assessment of the protein binding in pooled uremic serum. The
free fraction of CRO in the three rats of the Control Group was

unusually high. The pooled rat serum from this study (Table 6)

and from other studies (Table 3 in Chapter IV and Table 2 in
Appendix A) exhibited a consistent low free fraction of CRO.
Since we were only able to collect sufficient serum to perform

protein binding studies from 3 rats and the results from these
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rats are inconsistent with all of our other observations ,

it is

presumed that some technical error was responsible for this

observation and these data were not further analyzed.
The renal excretion and renal clearance of CRO were reduced
to near zero in the UN treated rats confirming that severe renal
failure was produced. The log serum concentration-time profile

clearly demonstrated that CRO had at least two pharmacokinetic
compartments in rats with or without renal failure. Furthermore,
the CL/ and t1/2 of CRO did not significantly change in the UN

treated rats which is similar to the data reported in the
majority of patients with renal failure (1).

However, it should be borne in mind that as a preliminary
study, the data obtained during these investigations are best

viewed as providing guidance for the more comprehensive studies

described in the next chapter.

Collectively, these initial observations suggest that the

cannulations of the common bile duct, duodenum, and femoral
artery can be performed in rats with UN induced renal
dysfunction. The model which was developed appears to have the

potential to allow the systematic study of CRO pharmacokinetics
with the goal of identifying the cause of the unanticipated long

half-life of this drug in a small subset of patients with renal
failure.
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Tabie 1. Evaluation of Pretreatment Effects (Surgical Preparation
and Overnight Fast with or without UN Injection)

on the Body

Weight, Hematocrit, and Serum Albumin Level of Rats

Group

Day 0

Day 3

Body Weight (g)

Control (n = 5)

365 ± 26

357 ± 27*

UN (n = 6)

370 ± 23

359 ± 28*

Hematocrit (%)
Control (n = 5)

50 ± 1

48 ± 2

UN (n = 6)

50 ± 1

49 ± 5

Albumin (g/dl)
Control (n = 5)

3.90 ± 0.51

2.69 ± 0.61*

UN (n = 6)

3.94 ± 0.34

2.43 ± 0.51*

(* p < 0.01, Day 0 vs. Day 3)
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Table 2. Evaluation of UN Treatment on the Serum Urea Nitrogen

Level of Rats

Group

Day O

Day 3

(mg/dl)

(mg/dl)

Control (n = 5)

21 ± 2

40 ± 14**

UN (n = 6)

21 ± 3

180 ± 31*

(

p < 0.01, “ p < 0.05, Day 0 vs. Day 3)
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Table 3. Biliary, Urinary, and Total Excretion of CRO (% of Dose)
over the 480 Minutes after Administration of a Single Dose (20

% of Dose

UN Treated Group

Control Group

(n = 6)

(n = 5)

o

Total Excretion

i+

i.v. bolus)

47.1 ± 31.7

77.7 ± 8.4

56.4 ± 31.9

78.4 ± 7.6**

104 ± 24

o

mg/kg,

Excreted in Urine

% of Dose
Excreted in Bile

% of Dose Excreted
in Urine and Bile

(* p < 0.01, ** p < 0.05, UN Treated Group vs. Control Group)
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Table 4. Mean Pharmacokinetic Parameter Estimates Derived from
the Serum Concentrations of Total CRO in Rats after
Administration of a Single Dose (20 mg/kg,

Parameter

i.v. bolus)

Control Group

UN Treated Group

(n = 5)

(n = 6)

CLst

(ml/min)

0.51 ± 0.25

0.63 ± 0.35

CL/

(ml/min)

0.31 ± 0.30*

0.01 ± 0.01

CLh/

(ml/min)

0.26 ± 0.17

0.38 ± 0.20

83.3 ± 30.2

166 ± 156a

149 ± 92

186 ± 91

Vdt

(ml) ,

Phase

t1/2 (min) , p Phase

(* p < 0.01, UN Treated Group vs. Control Group)

One rat in this group had extremely high Vdt (508 ml). When
the data from this rat was excluded the mean VdT was 97.3 ±
33.6 ml.
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Table 5. In Vitro Protein Binding of CRO in Pooled Serum from

Normal Rats

% Free CRO

Total Concentration
(Atg/ml)

20

5.2

100

6.0

200

14.9

300

25.5

400

34.1

500

40.4

649

46.7

800

54.0

62

Table 6. Mean Pharmacokinetic Parameter Estimates for Free CRO in
Rats after a Single Dose (20 mg/kg,

Parameter

i.v. bolus)

Control Group

UN Treated Group

(n = 3)

(n = 6)

CLsf

(ml/min)

2.30 ± 0.79

1.80 ± 1.09

CLrf

(ml/min)

1.24 ± 1.00 *

0.02 ± 0.03

Cl^/

(ml/min)

1.17 ± 1.24

1.19 ± 0.52

0.308 ± 0.089

0.375 ± 0.065

fa

(* p < 0.01, UN Treated Group vs. Control Group)

Since the reliability of the estimates of free fraction for
the control group in this chapter was in question, the
interpretation of these parameter estimates must be regarded
tentative at best.
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Figure 1. The serum concentrations of total CRO in control and UN

treated rats after administration of a single dose (20 mg/kg,
i.v. bolus).
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Chapter IV
Comprehensive Evaluation of the Uranyl Nitrate Induced Renal

Failure Model on the Pharmacokinetics of Ceftriaxone in the Rat
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Table of Abbreviation
Cfree = concentration of free CRO in serum
Cbound = concentration of bound CRO in serum
= biliary clearance of total drug

CL^/ = biliary clearance of free drug
CL^ = renal clearance of total drug

CLff = renal clearance of free drug
CL^ = systemic clearance of total drug

CLsf = systemic clearance of free drug
f = free fraction of CRO in serum

Vdr = apparent volume of distribution of total drug, p phase
t1/2 = half-life, p phase
n1 or n2 = number of apparently identical binding sites for CRO

on a particular serum protein
k, or k2 = association constant for the serum protein: CRO

complex
UN = uranyl nitrate
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ABSTRACT

A comprehensive study of the pharmacokinetics of ceftriaxone

(CRO) was performed in three groups of rats. Rats from the First
Control Group (-/- Group, n = 12) were not surgically prepared

and did not receive uranyl nitrate (UN) treatment. Drug
administration and limited blood sampling for these rats were
performed by tail vein puncture. This group of animals were

included to provide information regarding the influence of the

extensive surgery (with its associated blood loss,

hypoalbuminemia, etc.), the effect of ether anesthesia and the
consequences of moderate aging (about 6 weeks difference between

the "old" and "young" -/- Group rats) on CRO pharmacokinetics.
Rats in the Second Control Group (S/- Group, n = 15) were

surgically prepared. Cannulas were placed in the femoral artery

for blood sampling and CRO administration,

in the common bile

duct for bile collection, and in the duodenum for bile recycling

before the initiation of the study. UN Treated Group (S/UN, n =
15)

rats were surgical prepared identically to the S/- rats and

also received an injection of UN (10 mg/kg, s.c.). Finally, a
detailed study of the protein binding of CRO in pooled serum from
normal and uremic rats was performed.

The overall results of these studies support the
observations made in the small groups of rats used in our
previous experiments (see Chapter III) . Specifically, the half
life of CRO was slightly prolonged in the UN treated rats

compared to their surgically prepared controls (191 ± 110 vs.
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144

± 67 min). However, the biliary clearance of total drug was
similar in these two groups (0.42 ± 0.22 vs. 0.35 ± 0.22 ml/min)
even though the percent of the dose recovered in bile was

significantly greater in the UN treated rats (81.8 ± 19.5% vs.
44.1 ± 16.8%). The protein binding of CRO in pooled rat serum was
concentration-dependent with significantly lower binding in

uremic serum. The S/UN rats also had significantly reduced
protein binding of this drug. There was a fivefold difference in
the free fraction of CRO between the S/UN rats (0.194 ± 0.055)
and their controls (0.039 ± 0.055) at low CRO serum

concentration. Furthermore, the extensive surgical preparation
had little effect on the serum concentration-time profile of this
drug. Finally, the "young" and "old" Control Group rats (-/-)

exhibited a similar clearance of CRO.
In conclusion, the rat model of renal failure appears to be

satisfactory for the study of the factors controlling the
clearance/half-life of CRO in acute severe renal failure. This
model may also be useful to simultaneously study renal and
biliary clearance of other drugs in kidney dysfunction.
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INTRODUCTION

Ceftriaxone (CRO)

is a third generation cephalosporin with a

long half-life. This allows once a day treatment with this drug

for most infections (1-2). Also of significance, the majority of
patients with severe renal failure have only slightly increased

half-lives (12 hr vs. 8 hr)

(3). However, a small subset of

patients with renal failure exhibit strikingly prolonged half
lives (-30 hr)

(3). The reduced ability of this minority of

patients to eliminate CRO via biliary excretion will cause
ceftriaxone accumulation unless the dose is reduced.

It is

difficult to identify the causative mechanisms in patients
because of ethical and practical considerations. Therefore, the

principal purpose of the studies reported in this chapter was to

perform a comprehensive examination of the rat model of renal
dysfunction described in Chapter III in a statistically relevant
number of animals and to provide supplementary data on the model
itself (i.e.,

is there any readily recognizable hepatic damage

associated with uranyl nitrate (UN) administration or extensive
surgery? does the extensive surgical preparation of the rat alter

CRO pharmacokinetics? etc.).

MATERIALS AND METHODS
Materials

Analytical grade CRO was provided by Hoffmann-La Roche Inc.
(Basel, Switzerland). Rocephin* (Lot#0387) was used for

administration to the rats. Uranyl nitrate hexahydrate was from
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Fluka Chemie AG (Buchs, Switzerland). Tygon microbore tubing

(formulation S-54-HL, 0.015 in. ID x 0.030 in. OD x 0.075 in.
Wall) was obtained from Norton Performance Plastics Co.

(Akron,

OH) and polyethylene tubing (PE-60, 0.030 in. ID x 0.048 in. OD)
was specially ordered from the Clay Adams Division of Becton
Dickinson and Company (Parsippany, NJ). Silastic medical-grade

tubing (0.025 in. ID x 0.047 in. OD) was obtained from Dow
Corning Corporation (Midland, Michigan). All other chemicals were
of reagent grade or the best grade commercially available.

Animals
Male Sprague-Dawley rats (300-325 g) were purchased from

Harlan Sprague Dawley Inc.

(Indianapolis, IN) and maintained

on a 12 hr light/dark cycle with free access to food and

water. The research protocol and animal usage in these studies
were approved by the West Virginia University Animal Care and Use
Committee.
Surgical Procedures
The duodenal catheter was prepared by using polyethylene

tubing (PE-60) with one side attached to an approximately 2 cm

segment of Silastic medical-grade tubing. The catheters inserted
into the bile duct and femoral artery were made of Tygon

microbore tubing.

Rats were anesthetized with ether before surgery. To implant

bile duct and duodenal cannulas, a 2 cm midline incision was made
in the skin as well as underlying muscle of the abdomen. The

intestines were gently pushed aside with sterile gauze to allow
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visualization of the common bile duct and duodenum. A catheter

was inserted into the common bile duct in the direction of the

liver while the other side of the bile duct was ligated. Another
catheter was implanted into the duodenum near its junction with

the bile duct. Both catheters were tunneled subcutaneously and

exteriorized at the back of the neck and secured with a suture.
These two catheters were connected to each other to obtain near
normal bile circulation before the initiation of the CRO

pharmacokinetic study. The bile duct cannula was disconnected

from the duodenal cannula for collection of bile samples after
CRO administration. The abdominal muscle was closed with sterile

sutures and the skin was closed with sterile staples. A Tygon
catheter was also inserted into the left femoral artery for CRO

dosing and blood sampling. It was sutured to the adjacent tissue
and tunneled subcutaneously to the back of the neck, where it was
secured. Sterile saline containing heparin (100 u/ml) was

injected into the cannula to maintain patency and this canuula

was plugged with a T-pin. Rats were allowed 24 hr to recover from
the surgery before the CRO administration.

Animal Treatment
The pharmacokinetic studies of CRO involved three treatment

groups. First Control Group (-/- Group, n = 12) rats were not
surgically prepared and did not receive UN treatment. Second

Control Group (S/- Group, n =15) rats had surgical preparation
but no UN treatment. UN Treated Group (S/UN Group, n = 15)

rats

matched the S/- Group except the rats also received UN injection
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(10 mg/kg, s.c.). The -/- Control Group data was acquired by

studying 6 rats at the start of the series of investigations
(hence forth referred to as the "young -/- rats") and another 6

rats at the end of this series of experiments (hence forth

referred to as the "old -/- rats"). Approximately 6 weeks elapsed
between the CRO pharmacokinetic studies on these "young" and
"old" rats and the weight gain associated with aging was from 308

to 349 g.
On day 0, blank blood samples were obtained from all rats by

tail vein puncture. UN (10 mg/kg) in physiological saline
solution (10 mg/ml) was administered subcutaneously to the rats

of the S/UN Group at the beginning of day 1. An equal volume of
saline solution was given by the same route of administration to
the rats of the two control groups as a sham-treatment. Rats had

free access to food and water. Two days later, rats from the S/UN

Group and S/- Group were surgically prepared and fasted overnight
following the surgery but water was provided ad libitum. CRO was

dissolved in sterile saline and diluted to a final concentration
of 20 mg/ml less than one hour prior to dosing. All groups of

rats received a single dose of CRO (20 mg/kg, i.v. bolus) at the

beginning of day 4 through the indwelling cannula in the femoral
artery and this catheter was thoroughly rinsed with sterile

saline to prevent sample contamination. Rats in the -/- Group
received the same dose of CRO via a tail vein and blood samples
were subsequently obtained from a different tail vein pre-dose as

well as 75, 180, 360, and 480 minutes post dosing.
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The blood sampling schedule for the S/- and S/UN rats was
pre-dose as well as 10, 30, 75, 120, 180, 240,

360, and 480

minutes after the administration of CRO and the volume for each

sample was approximately 300 pl. Bile samples were collected pre
dose and over the intervals 0-30, 31-75, 76-120,

121-240, 241

360, and 360-480 minutes post dosing. The volume of each
collection was recorded. Urine excreted over the 480 minutes post

dosing was collected using a plexiglass metabolic cage and mixed
with urine obtained from the urinary bladder at the end of the

experiment for each rat. The volume of total urine was recorded
and aliquots were saved. A large volume of blood (4 ml) was taken

for serum protein binding determination of CRO at the end of the
experiment and before sacrificing each rat. Serum was separated

from blood by centrifugation. All serum, bile, and urine samples
were stored at -20°C until used. The hematocrit was measured for

each rat on day 0 and immediately before CRO administration (day
3) .

Assays
CRO concentrations in serum, bile, and urine samples were

determined by previously established HPLC methods (see Chapter
II). The albumin (Sigma Diagonostics* BCP Albumin, Sigma Chemical
Co.), urea nitrogen (Sigma Diagonostics* Urea Nitrogen, Sigma
Chemical Co.), and SORT (an index of hepatic function, Sigma

Diagonostics* GPT, Sigma Chemical Co.)
all blank serum samples.
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levels were measured for

In Vitro Protein Binding of CRO in Pooled Serum from Normal Rats

Normal or uremic blank blood was obtained by aortic stick

from six normal rats as well as from six uremic rats three days
after receiving UN injection (10 mg/kg, s.c.). Serum was

separated from red blood cells by centrifugation. Pooled normal
or uremic serum was spiked with CRO to various concentrations

(20, 60,

100, 150, 200,

300, 400, 500, 650, and 800 gg/ml). The

pH of serum (1 ml) was measured and adjusted to 7.40 ± 0.05. The
serum was immediately transferred to an ultrafiltration device

(Amicon Centrifree Micropartition system, Amicon Division, W. R.
Grace & Co., Danvers, MA) and centrifuged at 1,250 g for 10

minutes at 25°C. The filtrate was analyzed to estimate the free

concentration of CRO using the HPLC method described in Chapter
II. Scatchard analysis was employed to estimate the number of

binding sites (n) and the apparent association constant (k)

for

each site (4). In the present study, these parameters were
estimated using the program PCNONLIN (SCI Software Company,

Lexington, KT). Simple linear regression analyses (free fraction
of CRO vs.

[albumin]"1 as well as free fraction of CRO vs. serum

urea nitrogen concentration) were performed because previous

studies (5-6) or pharmacokinetic theory (7)

suggest that a linear

or near-linear relationship should exist between these

parameters. In addition, multiple stepwise regression analysis
was also performed to evaluate the cumulative effect of both

[albumin]'1 and urea nitrogen concentration on the free fraction
of CRO. This regression analysis was performed because it could
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provide added insight into the factors which might impact the
serum protein binding of CRO in rats with renal failure.
In Vitro Protein Binding of CRO in Serum from Each Individual S/-

or S/UN Rat

Serum (1 ml) of each rat was spiked with CRO to a
concentration of approximately 60 p.g/ml. The remainder of the
procedure for the estimation of free fraction was the same as
described above.

Pharmacokinetic Parameter Estimation Using PCNONLIN
The serum concentration-time data from each rat were fitted
using PCNONLIN to the equation:

C = A e"at + B e

where A and B are the coefficients of the biexponential equation
while a and 0 are the relevant macro rate constants. The area
under drug concentration-time curve (AUC0.480 mjn or AUC0.J was

calculated according to the linear trapezoidal method. The
various clearances,' t,1/2
,, and v/
of CRO were estimated for
d

individual rat using the following equations:
CL/ = (Total Amount of CRO in Urine) o.4ao mjn / AUC0.480 min
CLb/ = (Total Amount of CRO in Bile) 0.480 min / AUC0.480 min

CL/ = Dose / AUC0_
CL/ = CL//f

eV = citZ/f

cl/

= cl//f

t1/2 = 0.693/0

V/ = CL//0
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Statistical Analysis

Unless otherwise noted, all data were reported as the mean ±

one standard deviation. The null hypothesis (Ho) proposed for all
the comparisons was that there would be no differences observed

among sample means for all dependent measures. The null
hypothesis was tested using analysis of variance. JMP computer

software (SAS Institute Inc., Cary, NC) was used for the
statistical analysis. An alpha level of 0.05 was selected.

RESULTS

Evaluation of the Effects of Animal Preparation

The effects of pretreatment (surgical preparation and an
overnight fast with or without UN injection) on body weight,

hematocrit, SGPT, and serum albumin levels are summarized in
Table 1. Rats in the S/- and S/UN groups both lost approximately

3 to 4% of their body weight between day 0 and the time
immediately before the CRO administration (day 3). SGPT levels

increased moderately over the above time interval and the change

was similar between the UN treated rats and their controls.
During the surgical procedure of inserting the bile duct cannula,
the liver was gently manipulated to obtain a clear vision of the

bile duct. This might have done some minor damage to this organ

and led to the slightly increased SGPT level. Furthermore, over
the same time period, serum albumin concentration decreased 15 %

in the S/- Group but the change was not statistically
significant. However, consistent with this trend, a 25 % decrease
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in serum albumin concentration was observed in the S/UN Group (p

< 0.01). The hematocrit was slightly (not significantly) reduced
on day 3 in the S/- Group (surgical preparation and an overnight

fast) and in the S/UN Group (surgical preparation, an overnight
fast, and UN injection). Of critical importance, serum urea

nitrogen level increased approximately 10-fold in the S/UN Group
(p < 0.01), indicating that renal failure was successfully

induced (Table 2) . A trend toward an increase in serum urea
nitrogen was also seen in the S/~ Group. This increase may be due
to the combined effect of an alteration in the generation of urea

because of the overnight fast and the extensive

surgery/anesthesia which these animals received (with the
associated possibility of minor renal damage).
Serum Protein Binding

The protein binding data demonstrated that the free fraction
of ORO increased strikingly when the total concentration of this

drug increased from 20 to 800 [iq/ml (Table 3) . Additionally, the
free fraction of CRO was significantly greater in uremic serum

than normal serum at any given total concentration. When the free

fraction of CRO in serum was estimated for each individual rat at

a total concentration of 60 jiig/ml, the difference was highly
significant between the S/- and S/UN groups (0.039 ± 0.015 vs.
0.194 ± 0.055)

(Table 4). Furthermore, Scatchard analysis was

performed on the data from pooled normal or uremic serum (Figure

1). In Figure 1, each observed data point represents the mean
value of four experiments and the correlation coefficient between

78

observed and predicted Y values is 0.999 both in normal and

uremic serum. F-test for hierarchical non-linear models indicated
that the protein binding curves for pooled normal and uremic

serum were significant different (p « 0.001). This analysis also

provided the estimates of n1, n2, k1, and k2 which were optimized
using PCNONLIN (Table 5). These techniques suggested that CRO had

at least two distinct binding sites in serum and the binding
parameters were different between the two groups of rats.

Specifically,

the uremic serum exhibited a binding defect for

CRO. Since protein binding theory predicts that the free fraction

of a drug should be nearly an inverse function of the

concentration of its binding protein (5-7) and it is also well
known that uremia causes defective binding of drugs to albumin

(8), we performed simple linear regression analyses of CRO free

fraction vs.

[albumin]’1

(r2 = 0.228, p < 0.01; Figure 2) and vs.

serum urea nitrogen concentration (r2 = 0.749, p < 0.01; Figure

3). Multiple stepwise regression analysis (free fraction vs.
[albumin]’1 and urea nitrogen concentration) yielded only a

modest improvement in the fitting of the data (r2 = 0.758, p <
0.001; Figure 4).

Mass Balance Calculations
Mass balance data from all groups are presented in Table 6.

It is clear that UN treatment of the S/UN rats virtually
eliminated the kidney as an excretory organ for CRO since only

0.3% of the dose was recovered in their urine while control rats
yielded CRO recoveries of 19.6% and 26.6% of the dose in the -/-
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Group and S/~ Group, respectively. The biliary excretion of CRO
in the S/UN Group was 81.8% of the dose, which was double that in

the S/- Group (44.1% of dose)

(p < 0.001).

Serum Total Concentration-time Profiles
The total concentration-time curves of CRO exhibited two-

compartment pharmacokinetic behavior in both the S/UN and S/rats. However, the serum concentration was consistently higher in

rats with renal failure (Figure 5).

Comparisons of Pharmacokinetic Parameter Estimates (S/UN Rats vs.
S/- Rats)
The individual parameters defining the biexponential

equation which described the serum concentrâtion-time curve in
each rat were estimated using PCNONLIN and are listed in Tables 7

and 8. Furthermore, all other relevant pharmacokinetic parameters
were calculated and are listed in Tables 9 and 10. Mean

pharmacokinetic parameters of CRO are summarized in Table 11. The
systemic clearance was significantly lower in the S/UN rats than

in the S/- controls but similar biliary clearance was observed in
these two groups. The S/UN rats had no measurable recovery of CRO

in their urine and hence renal clearance was approximately zero.
Renal clearance in the rats with normal kidney function was 0.20
ml/min. The Vdt in the S/UN Group decreased approximately 31%

compared to that in the S/- Group while the t1/2 of CRO was
prolonged 33% in the rats with renal dysfunction. However,
neither of these changes reached statistical significance.
The renal clearance of free CRO in rats with renal failure
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(S/UN) was essentially zero. In the S/- rats its average value

was 5.38 ml/min (Table 4). Both the systemic clearance and
biliary clearance of free drug were significantly decreased in
the UN treated rats (Table 4).

Evaluation of the Effects of Surgical Preparation and Aging
Associated with the Length of the Experiment on the

Pharmacokinetics of CRO
Comparison of the S/~ and -/- groups demonstrated that the
extensive surgical preparation had little effect on the systemic

clearance of free or total drug (Table 12 and Figure 6).
Furthermore, the "young" and "old" control rats in the -/- Group

exhibited similar clearance, free fractions, and serum
concentration-time curves (Table 13 and Figure 7).

DISCUSSION
The studies described in this chapter provided further data

regarding the validity of our rat model of renal failure. The
renal clearance of CRO approached zero 3 days after UN treatment

and the biliary recovery of this antibiotic in these rats was
strikingly increased. This behavior closely paralleled that which
appears to occur in humans with severe renal dysfunction.

Furthermore, the half-life of CRO was not significantly different
between the S/UN and S/- groups. This is similar to the
observations made in humans. Finally, we have taken the

additional step of including a complete control group (-/-) which
had no surgical intervention, no anesthesia, and no UN treatment.
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The data from these animals strongly suggest that the extensive

surgery and ether anesthesia which the S/UN and S/- rats had

received did not influence CRO clearance (Table 12). Furthermore,

the approximately 13 % increase in body weight which occurred in
the rats over the 6 weeks required to carry out these studies did
not appear to impact CRO clearance (Table 13).

The serum protein binding of CRO in our rats was similar to
that seen in humans. Specifically, the free fraction of this drug

was concentration-dependent and the mean free fraction was always
higher in serum from animals with renal failure (Table 3).

Regression analyses suggest that only a small portion of the
increase in free fraction could be attributed to the moderate

hypoalbuminemia observed in the uremic rats. Indeed, most of the
binding defect observed in rats with renal failure was associated
with the magnitude of the elevation in serum urea nitrogen
concentration (r2 = 0.749; p < 0.01). One possible mechanism for
this increase in the free fraction of CRO might be the

accumulation of endogenous compounds in uremia. It has been

reported that a number of compounds which accumulate in humans

with renal failure avidly bind to serum proteins and displace a

variety of drugs from their binding sites (9). In addition, it
was also possible that the albumin in uremic serum was chemically
altered (carbamylated)

such that it did not have normal binding

sites (10-12).
Since control and uremic rats exhibited similar biliary
clearance of total CRO it appears that the renal failure did not
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change the biliary elimination rate of this drug. Somewhat

surprisingly, the free serum concentration of CRO in uremic rats

did not significantly effect its biliary clearance. This behavior
might be due to the accumulated chemicals which compete with this
antibiotic for hepatic uptake and/or biliary elimination.

It

appears that the significant decrease in the systemic clearance

of total CRO in rats with renal failure can be attributed to the

diminished renal clearance.
In summary, the rat model of renal failure appears to be

satisfactory for the study of the factors controlling the
clearance and half-life of CRO in acute severe renal failure.
This model may also be useful to simultaneously study the renal
and biliary clearance of other drugs in kidney dysfunction.

83

REFERENCES
1. L. A. Mandell, M. G. Bergeron, A. R. Ronald, C. Vega, G.
Harding and R. Saginur. Once-daily therapy with ceftriaxone
compared with daily multi-dose therapy with cefotaxime for
serious bacterial infections : a randomized, doubled blind study.
J. Infect. Dis. 160:433-441 (1989) .

2. C. R. Smith, B. G. Petty, C. W. Hendrix, W. N. Kernan, P. L.
Garver and K. Fox. Ceftriaxone compared with cefotaxime for
serious bacterial infections. J. Infect. Dis. 160:442-447 (1989).
3. K. Stoeckel, P. J. McNamara, G. Hoppe-Sey1er, A. Blumberg and
E. Keller. Single-dose ceftriaxone kinetics in functionally
anephric patients. Clin. Pharmacol. Ther. 33 :633-641 (1983).

4. G. Scatchard. The attractions of proteins for small molecules
and ions. Ann. NY Acad. Sci. 51: 660-672 (1949).

5. P. J. McNamara, D. Laika and M. Gibaldi. Endogenous
accumulation products and serum protein binding in uremia. J. Lab.
Clin. Med. 98:730-740 (1981) .
6. R. J. Porter and R. B. Layzer. Plasma albumin concentration
and diphenylhydantoin binding in man. Arch. Neurol. 32:298-303
(1975).

7. D. J. Birkett. The importance of unbound drug. Agents Actions
Suppl. 17:79-84 (1985).
8. W. D. Hooper, F. Bochner, M. J. Eadie and J. H. Tyrer. Plasma
protein binding of diphenylhydantoin: effects of sex hormones,
renal and hepatic disease. Clin. Pharmacol. Ther. 15 :27 6-282 (1974).

9. W. A. Craig, M. A. Evenson, K. P. Sarver and J. P. Wagnild.
Correction of protein binding defect in uremic sera by charcoal
treatment. J. lab. Clin. Med. 87 : 637-647 (1976) .
10. D. W. Shoeman and D. L. Azarnoff. The alteration of plasma
proteins in uremia as reflected in their ability to bind
digitoxin and diphenylhydantoin. Pharmacology 7:169-177 (1972).
11. S. W. Boobis. Alteration of plasma albumin in relation to
decreased drug binding in uremia. Clin. Pharmacol. Ther. 22:147-153
(1977).
12. S. Erill, R. Calvo and R. Carlos. Plasma protein
carbamylation and decreased acidic drug protein binding in
uremia. Clin. Pharmacol. Ther. 27:612 -618 (1980).

84

Table 1. Evaluation of Pretreatment Effects (Surgical Preparation

and Overnight Fast with or without UN Injection) on the Body
Weight, Hematocrit, Serum Albumin, and SGPT Levels of Rats
Group

Day 0

Day 3

Body Weight (g)
S/- (n = 15)

344 ± 18

333 ± 15*

S/UN (n = 15)

345 ± 17

331 ± 16*

Hematocrit (%)
S/- (n = 15)

44 + 3

43 + 3

S/UN (n = 15)

45 ± 4

43 + 5

Albumin (g/dl)

S/- (n = 15)

2.18 ± 0.58

1.86 ± 0.28

S/UN (n = 15)

2.35 ± 0.55

1.76 ± 0.28*

SGPT (u/1)
S/- (n = 15)

42 ± 15

150 ± 97*

S/UN (n = 15)

49 ± 14

126 ± 159

(* p < 0.01, Day 3 vs. Day 0)
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Table 2. Evaluation of UN Treatment on the Serum Urea Nitrogen

Level of Rats

Group

Day 0

Day 3

(mg/dl)

(mg/dl)

S/- (n = 15)

20 ± 7

45 ± 24*

S/UN (n = 15)

22 ± 11

182 ± 31*

(* p < 0.01, Day 3 vs. Day 0)
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Table 3. In Vitro Protein Binding of CRO in Pooled Serum from

Normal or UN Treated Rats
Total Concentration

% Free CRO

(gg/ml)

Normal Serum

Uremic Serum

20

4.8

17.4

60

4.8

20.2

100

7.0

24.4

150

10.2

31.5

200

14.4

35.8

300

25.6

43.6

400

33.3

50.7

500

42.6

55.8

650

46.4

59.7

800

53.5

61.5
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Table 4. Mean Pharmacokinetic Parameter Estimates for Free CRO in
Rats after a Single Dose (20 mg/kg, i.v. bolus)
Parameter

S/UN Group

S/~ Group

(n = 12)

(n = 13)

CLrf

(ml/min)

0.00 ± 0.00*

5.38 ± 4.71

CL^/

(ml/min)

2.80 ± 1.58*

f

0.194 ± 0.055*

(* p < 0.01, S/UN vs. S/-)
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in

19.9 ± 10.2

co

2.71 ± 1.38*

+i

(ml/min)

co

CLsf

0.039 ± 0.015

Table 5. Parameter Estimates from Scatchard Analysis of CRO
Protein Binding in Pooled Serum from Normal or UN Treated Rats
Normal Rat Serum

Uremic Rat Serum

Mean ± SE

Mean ± SE

ni

0.74 ± 0.07

0.52 ± 0.12

n2

1.81 ± 0.75

2.92 ± 1.53

0.0681 ± 0.0112

0.0271 ± 0.009

0.0008 ± 0.0006

0.0005 ± 0.004

Parameter

k,

(M'1)

k2 (M"1)

SE: Standard Error
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Table 6. Total Biliary and Urinary Excretion of CRO (% of Dose)

over the 480 Minutes after a Single Dose (20 mg/kg,
Group

i.v. bolus)

Total

Total

Biliary Excretion

Urinary Excretion

-/- (n = 12)

-

19.6 ± 4.6

S/- (n = 15)

44.1 ± 16.8

26.6 ± 20.8

S/UN (n = 15)

81.8 ± 19.5*

0.3 ± 0.8*

(* p < 0.01, S/UN vs. S/- or -/" )
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Table 7. Estimated Parameters (Estimate ± Standard Error)
Describing the Biexponential Decline of Serum CRO Concentration

in Each Individual Rat from the S/- Group

Rat

A

B

a

/3

ID

(pg/mi)

(pg/ml)

min"1

min"1

4

44.4 ± 9.7

93.1 ± 4.3

0.0805 + 0.0320

0.0070 + 0.0004

6

67.0 ± 3.0

40.2 ± 2.2

0.0496 + 0.0049

0.0044 ± 0.0003

8

94.8 ± 17.1

71.9 ± 6.8

0.0998 + 0.0310

0.0121 + 0.0009

10

86.4 ± 7.9

10.8 ± 9.0

0.0157 + 0.0025

0.0031 + 0.0020

0.0108 ± 0.0023

0.0025 + 0.0036

12

85.9 ± 16.2 10.0 ± 17.8
20.0 ± 8.9

0.0183 ± 0.0038

0.0037 + 0.0012

16

72.5 ± 3.6

43.8 ± 4.8

0.0645 + 0.0084

0.0111 ± 0.0009

18

76.6 ± 8.3

59.6 ±

0.0787 + 0.0230

0.0114 + 0.0013

0.0234 + 0.0064

0.0050 + 0.0015

0.0381 ± 0.0068

0.0028 + 0.0004

0.0158 ± 0.0027

0.0052 ± 0.0008

20

22

24

(N

69.1 ± 7.8

CO

14

85.5 ± 11.8 27.4 ± 13.1
81.1 ± 6.1

60.2 ± 4.9

70.0 ± 11.7 38.5 ± 12.9

28

154 ± 47

76.2 ± 6.9

0.119 ± 0.041

0.0104 + 0.0008

30

82.4 ± 7.1

11.3 ± 7.8

0.0240 + 0.0043

0.0043 + 0.0025

32

92.0 ± 2.9

52.5 ± 1.7

0.0572 + 0.0036

0.0043 + 0.0002

0.0224 ± 0.0040

0.0058 + 0.0015

34

Mean
± SD

84.4 ± 10.0 27.4 ± 11.6

83.1

± 22 4

0.0478

42.9

± 24. 9

± 0.0330
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0.0062

± 0.0033

Table 8. Estimated Parameters (Estimate ± Standard Error)
Describing the Biexponential Decline of Serum CRÛ Concentration

in Each Individual Rat from the S/UN Group

Rat

A

B

a

P

ID

(pg/ml)

(pg/ml)

min"1

min"1

1

72.5 ± 9.6

39.6 ± 10.9

0.0172 ± 0.0035

0.0039 ± 0.0007

3

78.7 ± 5.6

62.8 ± 5.1

0.0431 ± 0.0071

0.0044 ± 0.0004

5

75.7 ± 6.0

54.0 ± 6.9

0.0430 ± 0.0072

0.0067 ± 0.0008

7

61.1 ± 7.3

45.6 ± 8.5

0.0344 ± 0.0062

0.0074 ± 0.0010

9

62.1 ± 5.8

62.0 ± 5.2

0.0564 ± 0.0121

0.0066 ± 0.0006

11

76.5 ± 7.5

76.9 ± 2.6

0.0712 ± 0.0116

0.0040 ± 0.0002

15

113 ± 14

112 ± 1

0.115 ± 0.015

0.0048 ± 0.0001

17

102 ± 8

59.1 ± 6.2

0.0649 ± 0.0112

0.0074 ± 0.0008

21

89.0 ± 6.7

18.9 ± 7.5

0.0187 ± 0.0026

0.0038 ± 0.0011

23

135 ± 8

75.2 ± 5.4

0.0413 ± 0.0054

0.0027 ± 0.0003

0.0212 ± 0.0122

0.0040 ± 0.0015

25

79.4 ± 23.4 55.0 ± 26.4

27

120 ± 10

100 ± 3

0.0336 ± 0.0102

0.0013 ± 0.0001

29

79.7 ± 11.9

86.5 ± 3.1

0.0685 ± 0.0156

0.0021 ± 0.0002

31

51.0 ± 6.9

68.2 ± 2.9

0.0519 ± 0.0122

0.0046 ± 0.0002

33

81.3 ± 2.7

58.0 ± 2.1

0.0427 ± 0.0032

0.0037 ± 0.0002

Mean

85.1

± SO

± 22.3

65.0

± 22.6
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0.0482

0.0045

± 0.0243

± 0.0018

Table 9. Pharmacokinetic Parameter Estimates of CRO for Each
Individual Rat from the S/- Group

cl;

eV

(nl/nin)

(ml/min)

(ml/min)

(ml)

(min)

14500

0.42

0.26

0.14

60.2

99

6

11000

0.57

0.37

0.24

129

158

8

889

0.74

0.06

0.53

61.3

57

10

9030

0.70

0.25

0.45

223

221

12

11800

0.59

0.00*

0.17

241

283

14

9610

0.71

0.39

0.40

193

187

16

6090

1.03

0.35

0.75

92.4

62

18

6980

0.93

0.38

0.68

81.8

61

20

9610

0.70

0.41

0.30

139

137

22

27000

0.27

0.12

0.16

94.2

245

24

12200

0.55

0.13

0.12

106

134

28

9650

0.73

0.00*

0.36

69.9

67

30

6340

1.09

0.27

0.75

255

163

32

13700

0.51

0.00*

0.05

118

162

34

18200

0.37

0.00*

0.22

64.4

120

Rat

AUG

ID

(/izg.min/ml)

4

cl;

v;

t1/2

These urine specimens did not contain measurable levels of
CRO. While this was surprising, there was no satisfactory
objective basis to exclude these data from the overall
pharmacokinetic analysis. Therefore they were included.
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Table 10. Pharmacokinetic Parameter Estimates of CRO for Each

Individual Rat from the S/UN Group
CLr'

eV

(ml/min)

(ml/min)

(ml/min)

(ml)

(min)

14900

0.40

0.00

0.38

104

180

3

16600

0.38

0.00

0.39

84.9

156

5

10900

0.57

0.00

0.53

85.3

103

7

8890

0.73

0.00

0.81

97.7

93

9

11500

0.59

0.00

0.61

88.8

105

11

21600

0.29

0.01

0.30

73.2

174

15

24600

0.28

0.00

0.25

57.2

143

17

10600

0.63

0.01

0.71

84.8

94

21

10000

0.67

0.00

0.74

176

181

23

36900

0.18

0.00

0.19

68.5

262

25

18400

0.37

0.00

0.38

93.1

173

27

82700

0.08

0.00

0.05

59.7

528

29

49800

0.14

0.00

0.14

67.6

338

31

16500

0.43

0.00

0.45

95.5

152

33

18200

0.39

0.00

0.30

105

187

Rat

AUG

ID

(jUg.min/ml)

1

CL.'

94

Vd*

t1/2

Table 11. Mean Pharmacokinetic Parameter Estimates for the S/UN

and S/- Rats

Parameter®

S/UN Group

S/- Group

(n = 15)

(n = 15)

CL/

(ml/min)

0.41 ± 0.19*

0.66 ± 0.22

CL/

(ml/min)

0.00 ± 0.00*

0.20 ± 0.16

CL^/

(ml/min)

0.42 ± 0.22

0.35 ± 0.22

89.4 ± 27.3

129 ± 65

191 ± 110

144 ± 67

V/

(ml) , (3 Phase

t1/2 (min) , (3 Phase

(* p < 0.01, S/UN vs. S/-)

AUC0-ix calculated using PCNONLIN was slightly lower for most
rats (linear trapezoidal method vs. PCNONLIN: 11600 ± 5150
vs. 10300 ± 4370 /ïg.min/ml in the S/- Group; 23500 ± 19100
vs. 22100 ± 18000 jUg.min/ml in the S/UN Group) . Therefore,
CL^ and Vdt calculated using the AUCq.* estimated using
PCNONLIN were slightly different from the data of Table 11
(S/UN Group: CL/ = 0.43 ± 0.21 ml/min and V/ = 94.4 ± 28.0
ml; S/- Group: CLst = 0.74 ± 0.25 ml/min and V/ = 141 ± 61
ml). Data in this footnote were expressed as mean ± one
standard deviation.
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Table 12. The Effect of the Surgical Preparation on Total or Free

Systemic Clearance of CRO after a Single Dose (20 mg/kg, i.v.

bolus)

in Rats

Group

CLS<

CL,'

Free Fraction

(ml/min)

(ml/min)

-/- Group

0.74 ± 0.36

17.9 ± 7.3

0.041 ± 0.006

S/- Group

0.66 ± 0.22

19.9 ± 10.2

0.039 ± 0.015
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Table 13. The Effect of Aging Associated with the Length of the
Experiment on Total or Free Systemic Clearance of CRO after a

Single Dose (20 mg/kg, i.v. bolus)
Rat

"Young"

cl;

in Rats

CL,'

Free Fraction

(ml/min/kg)

(ml/min/kg)

2.29 ± 0.71

61.5 ± 17.3

0.037 ± 0.003

2.14 ± 1.14

46.8 ± 21.2

0.045 ± 0.006

-/- Group

"Old"
-/- Group
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Figure 1. Protein binding of CRO in pooled normal or uremic
serum. Protein binding data were plotted according to the method
of Scatchard. Each observed data point represents the mean value

of four experiments. Curves were generated from the binding

parameter estimates determined by PCNONLIN.
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Protein Binding of CRO in Rat Serum
Scatchard Analysis
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Figure 2.

Linear regression relationship between the free

fraction of CRO in serum and the reciprocal of serum albumin
concentration in rats (r2 = 0.228, p < 0.01).
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Figure 3.

Linear regression relationship between the free

fraction of CRO in serum and serum urea nitrogen concentration in
rats (r2 = 0.749, p < 0.01).
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Free Fraction of CRO vs. Urea Nitrogen Concentration
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Figure 4. Multiple stepwise regression analysis of CRO free
fraction and the reciprocal of serum albumin concentration as
well as serum urea nitrogen concentration in rats (parameter

estimates :

[albumin] "1 coefficient = 0.0182

intercept = 0.0251;

g/dl; urea nitrogen concentration coefficient = 0.0008 dl/mg;

overall, r2 = 0.758, p <

0.01).
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Multiple Regression

Observed Free Fraction

0.4 -I

0.3 -

0.2 -

0.1

0.0 —

0.0

0.1

0.2

Predicted Free Fraction

105

0.3

Figure 5. The log serum concentrations of total CRO in the S/and S/UN groups after a single dose (20 mg/kg,
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i.v. bolus).
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Figure 6. Comparison of serum concentration-time profiles of
total CRO in the S/- rats and their controls (-/- Group) after a
single dose (20 mg/kg, i.v. bolus).
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Figure 7. Comparison of serum concentration-time profiles of

total CRO between the "young" and "old" rats in the -/- Group

after a single dose (20 mg/kg, i.v. bolus).
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Chapter V
Alterations of Ceftriaxone Biliary Clearance and Excretion

by a Model Bile Acid (Tauroursodeoxycholate)

in Healthy

Rats and Those with Uranyl Nitrate Induced Renal Failure
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Table of Abbreviation

CLbi = biliary clearance of total drug
Ctotal = concentration of total CRO in serum
Cfree = concentration of free CRO in serum

UN = uranyl nitrate
TUDC = tauroursodeoxycholic acid, sodium salt
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ABSTRACT

The effect of renal failure on the biliary excretion of drugs

has not been adequately investigated. It would be of interest to
carefully document the existence of such effects and to develop

an understanding of the underlying mechanisms for any changes in

biliary clearance (CL^.) of drugs observed in renal failure
patients. This issue has become of increasing practical

importance because a number of new drugs depend on this pathway
for their elimination and these drugs are often used in patients
with renal dysfunction. Ceftriaxone (CRO) belongs to this group

of compounds and it has been reported that the excretion rate of

bile acids is significantly correlated with that of CRO in

healthy humans (p < 0.05, r = 0.83) . Because of this observation
and other supportive data, we hypothesized that CRO and bile
acids might share the same biliary transport system.

Tauroursodeoxycholic acid (sodium salt, TUDC) was selected as a

model bile acid to investigate the effect of this class of
compounds on the CL^ of CRO in the presence and absence of

severe renal failure. The selection of TUDC was based principally
on a series of advantages this bile acid provides and the current

controversy regarding whether TUDC shares the same biliary
transport system as CRO. It has been reported that TUDC inhibits

the biliary excretion of CRO while other investigators contend
that it does not share the same biliary transport carrier as CRO.

All rats were surgically prepared with cannulas and received
a loading dose (i.v. bolus) and a constant rate i.v.
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infusion of

CRO to attain and maintain a steady-state serum concentration of
this drug. Control rats (-/- Group) received the standard CRO
treatment only. TUDC Treated rats (-/TUDC Group) matched "-/

Group" except these rats were infused with TUDC (10 ^mol/kg/min).
Uranyl Nitrate (UN) and TUDC Treated rats (UN/TUDC Group) matched

"-/TUDC Group" except the rats also received UN treatment (10
mg/kg, s.c.).
In the TUDC treated groups,

it was observed that the

concentrations of bile acids in serum increased immediately
following the initiation of the TUDC infusion and quickly reached
steady-state.

In addition, the steady-state concentrations

returned to their previous levels after discontinuing the TUDC

infusion. In the control rats, the concentrations of bile acids
did not change over time. The CL^. of total CRO exhibited an

approximately 50% decrease during the TUDC infusion and the CL^.
of CRO recovered promptly after the discontinuation of TUDC

treatment. Interestingly, a small number of rats (13%) with
normal kidney function exhibited very low biliary excretions of

CRO and had unusually high concentrations of bile acids in serum
compared to their group mean. Collectively, these findings

support the hypothesis that TUDC reversibly inhibited the biliary
transport of CRO in rats with or without renal failure. Thus, CRO
appears to be at least partly excreted into bile via a transport

system shared with TUDC. A small subset of rats exhibited low
biliary excretion of CRO that might be attributable to an

inherently defective biliary transport system or to accumulation
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of substances which compete with this drug for this transport
system.
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INTRODUCTION

Ceftriaxone (CRO)

is a pharmacokinetically unique third

generation cephalosporin. It has a long half-life and its

clearance of total drug is relatively insensitive to severe renal
or hepatic failure (1-2). However, the mechanisms controlling the
biliary excretion of this antibiotic and virtually all other

drugs in renal failure have not been well studied. Therefore, it
would be of substantial interest to understand the underlying

mechanisms which influence biliary clearance of CRO. Based on the

normal volunteer data reported by Arvidsson et al.

(3), which

show that the excretion rate of bile acids is significantly
correlated with that of CRO in healthy humans (p < 0.05, r =

0.83), we speculated that the few renal failure subjects who

exhibit a striking decrease in non-renal (i. e., biliary)
clearance (1) do so mainly because they are not capable of
excreting appropriate amounts of selected bile acids and hence

the bile acid dependent component to biliary excretion is

decreased. It is also possible that some accumulated endogenous
compounds in renal failure (perhaps including selected bile acids

such as deoxycholates at sufficiently high concentrations) can
compete with CRO for excretion into the bile. Thus, we

hypothesized that CRO and bile acids may have the same biliary
transport carrier system. Tauroursodeoxycholate (TUDC) was used

in the present study as a model bile acid to investigate the

effect of this class of compounds on the biliary clearance of CRO
in the presence and absence of severe renal failure. The
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selection of TUDC was based principally on a series of advantages

this bile acid provides. Specifically, TUDC rarely induces
hepatic abnormalities in the rat even at high doses (4), its

metabolic fate is well understood (5) and its serum concentration
can be readily measured after dosing (6). The current controversy
regarding whether this bile acid shares the same biliary

transport system as CRO is another important reason for choosing

TUDC. Briefly, this controversy has arisen because Xia et al.

reported that TUDC inhibits the biliary excretion of CRO (7)

while others contend that it does not share the same biliary
transport carrier as CRO (8). For these reasons we used TUDC in

an effort to alter the biliary excretion rate of CRO in normal
and uremic rats in vivo. In addition, the results from the
conscious intact rats in this study could be compared to those
from the isolated perfused rat liver preparation infused by

ursodeoxycholic acid which is converted into TUDC in the rat
liver (9).

The goals of the present study were to determine the impact

of TUDC on the biliary transport rate of CRO, to characterize

selected aspects of the biliary canalicular transport carrier of
CRO, and to compare the possible differences of such transport

systems in conscious rats with or without renal failure.

MATERIALS AND METHODS
Materials
Analytical grade CRO was provided by Hoffmann-La Roche Inc.
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(Basel, Switzerland). Rocephin* from Hoffmann-La Roche Inc.

(Nutley, NJ, Lot #0405) was used for administration to rats.

Tauroursodeoxycholic acid (sodium salt, TUDC), was purchased from
Sigma Chemical Co.

(St. Louis, MO). Uranyl nitrate hexahydrate

was ordered from Fluka Chemie AG (Buchs, Switzerland). Tygon
micr.bore tubing (formulation S-54-HL, 0.015 in. ID x 0.030 in.
OD x 0.075 in. wall) was obtained from Norton Performance

Plastics Co.

(Akron, OH) and polyethylene tubing (PE-60, 0.030

in. ID x 0.048 in. OD) was order from the Clay Adams Division of

Becton Dickinson and Company (Parsippany, NJ). Silastic medical
grade tubing (0.025 in. ID x 0.047 in. OD) was from Dow Corning
Corporation (Midland, Michigan) and all other chemicals were of

the best grade commercially available.

Animals
Male Sprague-Dawley rats (300-325 g) were purchased from

Harlan Sprague Dawley Inc.

(Indianapolis, IN) and maintained on a

12 hr light/dark cycle with free access to food and water. The

research protocol and animal usage in these studies were approved
by the West Virginia University Animal Care and Use Committee.
Computer simulation

Estimates of CRO pharmacokinetic parameters from previous
studies in our laboratory (see Chapter IV) were used to simulate
CRO serum concentration-time curves and calculate doses of CRO in

rats with both normal and diminished renal function. The program
"STELLA"

(High Performance System, Inc., Hanover, NH) was

employed to accomplish this task. A two compartment model with
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elimination from the central compartment was used since CRO serum
concentration declined biexponentially in our previous studies
(Chapter IV). The input parameters were volume of the central

compartment (vol), apparent first-order elimination rate constant
from the central compartment (k10),

intercompartmental transfer

rate constants (k12 and k21) , and linear regression constants for

protein binding (a and b)

(intercept)

(Table 1). The input parameters "a"

and "b" (slope) were estimated from the linear

regression of free CRO concentration vs. total CRO concentration
from previous protein binding data (Table 3 in Chapter IV) when

the concentration range of total CRO was 20-150 ^g/ml.

Surgical Procedures
The duodenal catheter was prepared by using polyethylene

tubing (PE-60) with one side attached with an approximately 2 cm
Silastic medical-grade tubing, which was soft and suitable to

insert into the duodenum. The catheters inserted into the bile

duct,

femoral artery and vein were made of Tygon microbore

tubing.
Rats were anesthetized with ether before surgery. To implant
bile duct and duodenal cannulas, a 2 cm midline incision was made

in the skin as well as underlying muscle of the abdomen and the

intestines were gently pushed aside with sterile gauze to allow
visualization of the common bile duct and duodenum. A catheter

was inserted into the common bile duct in the direction of the
liver while the other side of the bile duct was ligated. Another

catheter was implanted into the duodenum near its junction with
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the bile duct. Both catheters were tunneled subcutaneously to be

exteriorized at the back of the neck. These catheters were then
secured with a suture and connected to each other outside of the
body to maintain near normal bile circulation until the

initiation of CRO pharmacokinetic study. The bile duct cannula

was disconnected from the duodenal cannula for collection of bile

samples after the initiation of the experiment. The abdominal
muscle was closed with sterile sutures and the skin was closed
with sterile staples. Vascular catheters were also placed into
the left femoral artery for blood sampling and in the left
femoral vein for the administration of CRO and TUDC. The cannulas

were sutured to the adjacent tissue and tunneled subcutaneously
to the back of the neck. Both cannulas were filled with sterile

saline containing heparin (100 u/ml) to maintain patency and were
plugged by using a T-pin. Rats were allowed 24 hr to recover from
the surgery before the initiation of the experiment.

Animal Treatment

The available animals were divided into three groups with
eight rats per group. All rats were surgically prepared with
cannulas and received a loading dose (i.v. bolus) as well as a

constant rate i.v. infusion of CRO to attain and maintain a
steady-state serum concentration. The control (-/- Group) rats

received the standard CRO treatment only (no TUDC or UN
treatment). TUDC treated (-/TUDC Group) rats matched "-/- Group"

except the rats had TUDC treatment. UN and TUDC treated (UN/TUDC
Group) rats matched "-/TUDC Group" except that the rats also
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received UN treatment (10 mg/kg, s.c.).
On day 0, blank blood samples were collected from all rats

by tail vein puncture. Rats in the UN/TUDC Group received UN (10
mg/kg)

subcutaneously in physiological saline (10 mg/ml)

immediately following blank blood collection while an equal

volume of saline was given by the same route of administration to
the rats in the other two groups as a sham-treatment at the

beginning of day 1. Rats still had free access to food and water.
Two days later, all rats were surgically prepared and fasted
overnight following the surgery but water was provided ad libitum.

On the beginning of day 4, sterile intravenous solutions of CRO
were prepared for each group less than 1 hr prior to dosing. Rats

in the -/- Group were given CRO 34.8 mg/kg as the loading dose

(i.v. bolus) and a constant rate i.v. infusion (238 /xg/kg/min)
from time 0 to 360 minutes. The same treatment was given to the

rats in the -/TUDC Group except they also received a constant
rate i.v. infusion of TUDC (10 /xmol/kg/min)

from 180 to 270

minutes. This TUDC infusion rate was selected because it is

consistent with literature estimates for the partial saturation

of TUDC biliary excretion (V|j)ax = 30 ^mol/kg/min)
different dose of CRO (i.v. bolus:

in rats (6) . A

11.7 mg/kg; constant rate i.v.

infusion: 56.0 ^g/kg/min) was administered to rats in the UN/TUDC
Group because of the differences in estimates of the

pharmacokinetic parameters observed in our previous studies (see
Chapter IV). These doses were selected based on simulations which
were performed using "STELLA". The same constant rate i.v.
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infusion rate of TUDC

was employed in both the UN/TUDC and -

/TUDC groups because there was no basis to project a difference
in serum levels of this bile acid.
Sample Collection

Blood samples were collected through the cannula in the

femoral artery pre-dose as well as 90, 140,

270, 290,

160,

180, 230, 250,

340, and 360 minutes after the loading dose and

initiation of the constant rate infusion of CRO. The volume of
blood collected was 200 ^l for the first four samples which was

then increased to 550 pl for the remaining samples because of the

requirement to determine serum concentration of bile acids. Serum

was immediately separated from blood by centrifugation at 1,000 g
for 10 minutes at ~4°C. Bile samples were collected pre-dose as
well as at 0-90, 91-140, 141-180, 181-230, 231-270, 271-320, and
321-360 minute intervals. The volume of each collection was
recorded. Urine excreted from 0 through 360 minutes was mixed

thoroughly with that obtained from the urinary bladder from each
rat at the end of the experiment. Urine volume was recorded and

aliquots were saved. A large volume of blood (4 ml) was taken for

serum protein binding determination of CRO at the end of the
experiment (before sacrificing each rat). All serum, bile, and

urine samples were stored at -20°C until assayed.

Assays

CRO concentrations in serum, bile, and urine samples were
determined by previously established HPLC methods (see Chapter
II). The serum concentration of bile acids was measured using
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commercially available assay kits (Sigma Diagonostics* Bile Acid,
Sigma Chemical Co.). The hematocrit, albumin (Sigma Diagonostics®

BCP Albumin, Sigma Chemical Co.), urea nitrogen (Sigma
Diagonostics* Urea Nitrogen, Sigma Chemical Co.), and SGPT (an
index of hepatic function, Sigma Diagonostics® G PT, Sigma
Chemical Co.) levels were measured for all blank serum samples.
Protein Binding of CRO in Serum from Each Individual Rat

The pH of serum (1 ml) separated from the large blood
specimen drawn at the end of the experiment was measured and
adjusted to 7.40 ± 0.05 by adding 0.5 N orthophosphoric acid. The

serum was immediately transferred to an ultrafiltration device
(Amicon Centrifree Micropartition System, Amicon Division, W. R.

Grace & Co., Danvers, MA) and centrifuged at 1,250 g for 10
minutes at 25°C. The concentration of CRO in each filtrate was
determined.

Protein Binding of CRO in Pooled Serum from Normal Rats Spiked
with TUDC

Blank blood was obtained by aortic stick from six healthy
rats. Serum was separated from red blood cells by centrifugation

and pooled together. The serum was then spiked with CRO to the
desired concentration (-80 pg/ml)

and with TUDC to various

concentrations (-241, -482, and -964 pmol/1). Five replicates of
serum spiked with CRO and the various concentrations of TUDC were
subjected to ultrafiltration to estimate the free concentration

of CRO. The procedures were same as described above. The

concentrations of CRO and TUDC were selected based upon the
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results in the three animal groups from this study.
Statistical Analysis
All data were reported as the mean ± one standard deviation.

The null hypothesis (Ho) proposed for all the comparisons was
that there would be no differences observed among sample means

for all dependent measures. In each case, the null hypothesis was
tested by analysis of variance. The calculations were performed
using JMP computer software (SAS Institute Inc., Cary, NC). An

alpha level of 0.05 was selected.

RESULTS
"STELLA" Simulation
The concentrations of total and free CRO in serum over time

were simulated using "STELLA"

(Table 2). Serum concentrations of

free CRO but not its total concentrations were matched between

normal rats and rats with renal failure because pharmacokinetic
theory suggests that only unbound CRO should be available for

liver uptake and, therefore, biliary excretion. The simulated
concentration-time profiles also indicated that the steady-state

concentrations of CRO should be attained at approximately 90
minutes after the initiation of a loading dose and a constant

rate i.v. infusion of this drug. As a result, the first sampling
time was 90 minutes.
Evaluation of Pretreatment Effects on Rats

Rats in all groups lost approximately 5% of their body

weight after the surgery and an overnight fast with or without UN
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treatment (Table 3). The hematocrits in all groups of rats were

observed to be moderately decreased on day 3 (immediately before
the CRO administration) and a modest increase in SGPT levels were
observed in all groups (Table 3 and Table 4). Finally, serum

albumin levels were significantly decreased and the magnitude of
this decrease was greater than that observed in previous studies

(Chapter III & IV). Of significance, the changes of the body
weight, hematocrit, albumin concentration, and SGPT level were
consistent across the three groups. Of greatest significance, the

urea nitrogen level dramatically increased from 28 to 190 mg/dl
in the UN/TUDC Group while no statistically significant changes
were noted in the sham-treatment groups (Table 4).

Concentration of Bile Acids in Serum

The concentrations of bile acids in serum increased
immediately following the initiation of the constant rate i.v.

infusion of TUDC and quickly reached steady-state conditions in
the -/TUDC and UN/TUDC groups (Figure 1). Steady-state

concentrations of bile acids were returned to their previous
levels after discontinuing the TUDC infusion. Interestingly, the

steady-state concentrations of bile acids were significantly
greater in rats with normal kidney function (-/TUDC Group) than
in those with renal failure (UN/TUDC Group). The bile acid levels

did not change with time in the control rats (Figure 1). The

clearance of bile acids in the UN/TUDC Group was higher than that
in the -/TUDC Group (33.9 ± 15.5 vs. 24.8 ± 13.8 ml/min/kg) but
the difference did not reach statistical significance.
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The Effect of TUDC Treatment on Biliary Clearance of CRO under

Steady-state Conditions
The biliary clearance was estimated using the following
equation:

CLb-ti'tz = (Amount of CRO in Bile)t1.t2 / AUCt1-t2

The CLbj of CRO during the 181-270 min interval of the TUDC
infusion exhibited an approximately 50 % decrease (p < 0.05)

compared to its previous control period (91-180 minutes)

in both

TUDC treated groups (Figure 2). Interestingly, after
discontinuing the TUDC infusion, the CL^ of CRO (271-360
minutes)

returned to the level of previous control period (Figure

2). The percent of the dose recovered in bile per unit time
demonstrated similar decreasing and increasing trends over the
same intervals (Figure 3). The -/- control rats exhibited little

change in either CL^ or excretion of CRO (Figure 2-3). These

results confirmed that TUDC reversibly inhibited the biliary
transport rate of CRO in normal and uremic rats.
Mass Balance Data

Similar biliary and urinary excretion of CRO (% of dose)

over the 360 minutes experimental period was found between the
-/- and -/TUDC rats (Table 5). As would be anticipated, rats with

renal failure yielded a significantly greater biliary excretion
and diminished urinary excretion of CRO over the same time period

(Table 5).
Serum Concentration of Total CRO

Steady-state serum concentrations of CRO were reached at 90
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minutes in all groups after giving the loading dose and the

constant rate i.v. infusion of this drug (Figure 4). The ability

of "STELLA" to predict the observed serum concentration-time

curves is depicted in Figures 5a and 5b. The -/- and -/TUDC (rats
with normal kidney function)

exhibited serum concentration-time

curves which closely resemble the simulated curve (Figure 5a).
However the simulated serum concentrations in the UN/TUDC rats

were consistently less (-15%) than those observed in rats with

renal failure (Figure 5b). Overall,

it appears that the simulated

data were consistent with the observed data.
Protein Binding of CRO for Each Individual Rat
Available evidence suggests that the freezer in which serum
samples for protein binding determinations were stored was
accidently unplugged. What is unequivocal is that these samples

were discovered at room temperature and it is believed that they
had been at this temperature for several days. Free fractions of

CRO in these samples were compared with the previous acquired
comprehensive protein binding data (Table 3 in Chapter III as
well as Tables 3 and 7 in Chapter IV)

(footnote a) and they were

much higher (Table 6). It can be argued that the degradations of

The protein binding data in pooled serum (Chapter III and
Chapter IV) and individual rat serum (Chapter IV) were
consistent and the free fractions of CRO were less than 0.15
for normal serum and 0.36 for uremic serum when the
concentration of total drug was lower than 200 pg/ml. The
only exception was that the six rat serum samples (Table 6
in Chapter III) exhibited higher free fraction, which was
believed due to the technical error.
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CRO and serum albumin in these samples under such unusual storage

conditions might be expected (10, 11) and this chapter is written
under the assumption that no meaningful data on CRO protein
binding were obtained. To experimentally verify that improper

storage leads to a striking increase in CRO free fraction in rat
serum, a supplementary series of experiments were performed and

the results of these studies strongly support this conclusion
(see Appendix A).
Effect of TUDC on Protein Binding of CRO in Pooled Serum from

Normal Rats
Ursodeoxycholic acid and TUDC are reported to bind to human

serum albumin (12). Collection of a large volume blood in the

middle of this in vivo animal experiment for studying possible
protein binding interaction of TUDC and CRO was impractical.
Therefore, pooled rat serum was used to examine protein binding

change of CRO by TUDC. It is clear that TUDC inhibited protein

binding of CRO and the inhibition was concentration dependent
(Table 7). When the concentration of TUDC in serum was 964 pg/ml,
the free fraction of CRO was three times that of control serum

(without TUDC).

Characterization of a Small subset of Rats
It was observed that two rats with normal renal function
exhibited extremely low biliary excretion of CRO (Table 8). Since
their serum concentrations and urinary excretion rates of CRO

were normal as were their bile flow rates, it appears that these

parameters could not explain this unusual biliary excretion
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behavior. The normal bile volume collected also suggests that
their bile duct cannulas were functioning properly.

Interestingly, the serum concentrations of bile acids in these

rats were much higher than their group means (Table 9).

Therefore, the higher serum concentration of bile acids seems to
be related to the lower biliary excretion of CRO in these

unusual rats.

DISCUSSION
The comparisons of observed and simulated serum

concentration-time curves of CRO revealed that " STELLA11
performed relatively well. The changes in the body weight,
hematocrit, albumin concentration, and SORT level were consistent

across three experimental groups, indicating that the UN
treatment did not meaningfully affect these values. During the
surgical procedure of inserting the bile duct cannula, the liver

was gently manipulated to obtain a clear vision of the bile duct.
This might have done some minor damage to this organ and led to

the slightly increased SORT level. The remarkably enhanced urea

nitrogen concentrations in serum in the UN/TUDC Group confirmed
that renal failure was successfully induced in this group of

rats.
There was no bile acid accumulation before the TUDC infusion
in rats with renal failure because the serum concentration of

bile acids at 180 min was similar among three groups (Figure 1).
In addition, it was not expected that rats with renal failure
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would have lower steady-state concentrations of bile acids in
serum than their controls since the same constant rate i.v.

infusion of TUDC was employed. It is impossible to offer a
reliable explanation for this behavior based on the available

data. However, several studies have evaluated the reserve
capacity for biliary excretion of compounds (13,

14) and it has

been suggested that this reserve capacity can be stimulated by

increased substrate concentrations (14-16). Therefore,

it is

possible that the reserve capacity stimulated by accumulated

endogenous substances in rats with renal failure resulted in the

higher biliary excretion of TUDC and consequently lower serum
concentration of bile acids. However, the failure of the biliary

clearance of CRO to increase in the rats with renal failure
(Figure 2) does not support this hypothesis. Roda et al. found
that bile acids including ursodeoxycholic acid and TUDC bind to

human serum albumin (12). Defective serum protein binding in

uremic rats might cause a higher free fraction of bile acids.
Since the clearance of bile acids in the -/TUDC Group (33.9

ml/min/kg) was one-third of the hepatic flow rate of the rat (-80
ml/min/kg), a higher free fraction could result in a higher
clearance, therefore, a lower serum concentration of bile acids.

The key finding in the present study was the dramatic impact

of the TUDC treatment on the CLbi of CRO. The CL^ of CRO in rats
was significantly inhibited by TUDC both in the presence and

absence of renal failure and the inhibition was reversible. The

inhibition of biliary transport of CRO by TUDC is also in
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agreement with one of the hypotheses which formed the basis for

the present study. CRO appears to completely or partly share the
same biliary canalicular transport system with the model bile

acid TUDC in conscious intact rats. In addition, renal failure

did not affect the TUDC inhibition of the biliary clearance of
CRO. It should be mentioned that Xia et al. also observed that

the infusion of TUDC (2-30 /imol/kg/min) caused a dose dependent

linear decrease in the biliary CRO output in rats with normal
kidney function (7) and that ursodeoxycholic acid (10
pmol/kg/min)

inhibited the biliary CRO output in the isolated rat

liver (9), but our findings seem inconsistent with the results
reported by Oude Elferink et al. who observed that TUDC does not

inhibit CRO biliary secretion (8). The lack of inhibition
observed by Oude Elferink et al. might be due to the low i.v.

infusion rate of TUDC (5 /Jmol/kg/min) which was employed. It is
important to note that our findings provide some clarification
regarding this controversy. However, the current study does not

answer the question regarding the involvement of the organic

anion biliary canalicular transport system in CRO elimination. At
this point, this transport mechanism cannot be excluded from

having a role in the biliary excretion of CRO.

It has been

reported that bile acids (17-20) are considered to be excreted
from the hepatocytes into bile by ATP-dependent canalicular

carriers. ATP-dependent transport of taurocholate across the
hepatocyte canalicular membrane is mediated by a 110-kDa

glycoprotein which binds ATP (19). More recently, Sippel et al.
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purified and identified the rat liver ecto-ATPase (an
approximately 110-kDa glycoprotein) as a canalicular bile acid
transport protein (21). Although this carrier protein is not yet

fully characterized, our speculation is that the biliary
transport system of CRO could be related to this protein. This

discovery by Sippel et al. holds the promise for further
experiments to unequivocally identify the biliary canalicular

carrier proteins for CRO.
An increased serum concentration of total CRO was expected

in normal and uremic rats during the TUDC infusion because this

bile acid inhibited the biliary clearance of CRO (Figure 2). In
contrast, concentration of total CRO in serum was slightly
decreased in the -/TUDC Group and did not change in the UN/TUDC

Group during the TUDC administration (Figure 4). This might be
due to the inhibition of CRO protein binding by TUDC (Table 7),

which led to a higher concentration of free CRO in serum and more

CRO was distributed into peripheral compartment. Theoretically,
the decreased protein binding of CRO by TUDC might also lead to a
higher biliary clearance of this drug. However, this was not

observed perhaps due to the inhibition of the biliary clearance
of CRO by TUDC.

Interestingly, a small number of rats with normal renal
function exhibited strikingly lower biliary excretion of CRO and
significantly higher serum concentrations of bile acids. This

leads to the speculation that these few rats had an inherently
defective biliary transport system for CRO and/or substances that
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compete with this drug. This explanation may be extrapolated to

the few patients with severe renal disease who exhibit

exceptionally long half-lives (1). To be more specific, these

patients might also have an inherently defective biliary
transport system for CRO caused by renal failure or perhaps more
probably unusually high levels of one or more endogenous
compounds that accumulate in renal failure which inhibit biliary
excretion of this drug. These mechanisms may also explain the

substantial interindividual variation in the biliary excretion of
CRO in healthy humans (3, 22).

In clinical medicine, reversible CRO-associated biliary

pseudolithiasis has been reported and hence was of concern (23

26). This adverse effect appears to be due to saturating
concentration of CRO in the bile of patients. Since TUDC was

found to inhibit CRO biliary excretion in rats in the present

study, it may be possible that the addition of TUDC or
ursodeoxycholate to the CRO treatment (especially high dose)

might be capable of preventing or reversing the pseudolithiasis.
In conclusion, TUDC inhibits the CL^. of CRO in rats. This

inhibition is reversible and is similar in the presence or
absence of renal failure. Thus, CRO appears to be completely or

partly secreted into bile via a bile acid canalicular carrier in
normal and uremic rats. A small subset of rats with normal renal

function had extremely low biliary clearance of CRO and

significantly higher concentrations of bile acids in serum. It is

not possible to draw firm conclusions about the exact mechanism
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responsible for the unusual behavior in these few rats. However,
the possible explanations for the behavior are these rats include
an inherently defective biliary transport system that dominates

the excretion of at least some bile acids and CRO or the

accumulation of other competitive substances for this transport
system.
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Table 1. CRO Pharmacokinetic Parameter Estimates Required for
Computer Simulation Using "STELLA"
Rats

Parameters

Rats

with Normal Kidney

(r2 = 0.944)

with Renal Failure

-6.00 (r2 = 0.972)

a

-2.63

b

0.111 (r2 = 0.944)

klO (min"1)

0.0141

0.009

(min"1)

0.0185

0.0196

k21 (min1)

0.0238

0.0269

vol (ml)

56.2

47.8

kl2
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0.337

(r2 = 0.972)

Table 2. Concentrations of Total and Free CRO in Serum Simulated
Using "STELLA"

Time

Rats with Normal Kidney
c
^total

Cfree

(min)

(Mg/ml)

0

206

20.3

50

108

60

(Mg/ml)

Rats with Renal Failure
c
'"'free

(Mg/ml)

c

total

(Atg/ml)

21.3

81.0

9.4

9.5

45.9

105

9.0

9.1

44.8

70

103

8.8

8.8

44.1

80

102

8.7

8.7

43.6

90

101

8.6

8.6

43.4

100

100

8.5

8.6

43.2

150

100

8.5

8.5

43.0

200

100

8.5

8.5

43.0

250

100

8.5

8.5

43.0

300

100

8.5

8.5

43.0

350

100

8.5

8.5

43.0

400

100

8.5

8.5

43.0
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Table 3. Evaluation of Pretreatment Effects (Surgical Preparation

and Overnight Fast with or without UN Injection) on the Body
Weight, Hematocrit, Serum Albumin, and SGPT Levels of Rats
Day 0

Group

Day 3

Body Weight (g)

-/- (n = 8)

408 ± 19

389 ± 18*

-/TUDC („ = 7)

401 ± 10

379 ± 11*

UN/TUDC (n = 7)

396 ± 11

376 ± 14*

Hematocrit (%)

-/- (n = 8)

48 ± 3

43 ± 4**

-/TUDC (n = 7)

47 ± 2

41 ± 5**

UN/TUDC (n = 7)

48 ± 2

43 ± 3**

Albumin (g/dl)
-/- (n = 8)

3.20 ± 0.21

1.64 ± 0.22*

-/TUDC (n = 7)

3.31 ± 0.29

1.83 ± 0.29*

UN/TUDC (n = 7)

3.27 ± 0.43

1.41 ± 0.11*

SGPT (u/1)
-/- (n = 8)

67 ± 14

112 ± 34**

-/TUDC (n = 7)

61 ± 10

109 ± 48

UN/TUDC (n = 7)

72 ± 20

116 ± 67

(* p<0.01, ** p < 0.05, Day 3 vs. Day 0)
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Table 4. Evaluation of UN Treatment on the Serum Urea Nitrogen

Level of Rats
Day 0

Day 3

(mg/dl)

(mg/dl)

-/“ (n = 8)

33 ± 6

38 ± 25

-/TUDC (n = 7)

27 ± 3

46 ± 23

UN/TUDC (n = 7)

28 ± 7

190 ± 44*

Group

(* p < 0.01, Day 3 vs. Day 0)
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Table 5. Total Biliary and Urinary Excretion of CRO (% of Dose)
over the 360 Minutes after Initiation of the Loading Dose and the

Constant Rate i.v. Infusion

Total

Total

Biliary

Urinary

Excretion

Excretion

-/- (n=8)

35.7 ± 17.9

43.9 ± 15.2

79.6 ±8.1

-/TUDC (n=7)

35.2 ± 20.8

44.7 ± 19.2

79.9 ± 18.8

UN/TUDC (n=7)

57.1 ± 10.5**

0.0 ± 0.0**

57.1 ± 10.5**

Group

Total
Recovery

(** p < 0.05, UN/TUDC vs. -/TUDC or -/-)
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Table 6. Protein Binding of CRO in Serum Samples Accidentally
Exposed to Room Temperature for Several Days

Group

Ctotai Range (Mean)

Free Fraction

(A/g/ml)
-/- (n=8)

-/"TUDC (n=7)

UN/TUDC (n=7)

64.1 to 130

(96.0)

42.5 to 201 (103)
29.9 to 81.7

144

(57.4)

0.314 ± 0.069
0.450 ± 0.211

0.470 ± 0.110

Table 7. The Effect of TUDC on the Protein Binding of CRO in

Pooled Serum from Normal Rats
TUDC Concentration

CRO Concentration

CRO Free Fraction

/Jmol/1

pg/ml

n = 5

0

79.9

0.052 ± 0.002

241

79.9

*0.066 ± 0.002

482

79.9

*0.087 ± 0.003

964

79.9

*0.150 ± 0.010

(* p < 0.01, 241 or 482 or 964 pmol/1 of TUDC vs.
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0 /Jmol/1 )

Table 8. Extremely Low Biliary Excretion of CRO (% of Dose)

over

the 360 Minutes in a Small Subset of Rats with Normal Renal

Function

-/- Group

-/TUDC Group

(pg/ml)

(A»g/ml)

Parameters

Rat 33

Population

Rat 32

Mean

Population
Mean

Total Biliary

Excretion

5.8*

37.9

1.2*

35.3

4.5

7.2

7.3

8.9

(% of Dose)
Total Bile Volume

(ml)

(* p < 0.01, Individual Rat vs. Group Mean)
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Table 9. Higher Serum Concentrations of Bile Acids for a Small
Subset of Rats with Normal Renal Function and Extremely Low
Biliary Excretion of CRO
Time

-/- Group

(min)

(pmol/1)

Rat 3 3

—/TUDC Group

(pmol/1)

Population

Rat 32

Population
Mean

Mean

180

176

38

39

15

230

149

35

1840

877

250

123

32

2200

897

270

100

28

1400

902

290

100

27

838

372

340

38

17

507

153

360

32

11

466

96
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Figure 1. The effect of the constant rate i.v. infusion of TUDC
(10 jxmol/kg/min) on the serum concentration of bile acids.
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Figure 2. The effect of the constant rate i.v. infusion of TUDC

(10 /nmol/kg/min) on the biliary clearance of CRO in normal and
uremic rats (* p < 0.01, ** p < 0.05, 90-180 vs.

150

181-271 minutes).
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Figure 3. The effect of the constant rate i.v. infusion of TUDC

(10 jtimol/kg/min) on the biliary excretion of CRO (% of dose)

in

normal and uremic rats (* p < 0.01, 91-180 vs. 181-270 minutes).
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Figure 4. The concentrations of total CRO in serum after

initiation of drug administration in all groups. The loading dose
of CRO (34.8 mg/kg for the -/- and -/TUDC groups,

11.7 mg/kg for

the UN/TUDC Group) was followed immediately by the constant rate
i.v.

infusion (238 /ig/kg/min for the -/- and -/TUDC groups, 56.0

Mg/kg/min for the UN/TUDC Group).
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Concentration of Total CRO (/.

Figure 5. Comparisons of the simulated and observed

concentration-time curves in rats with or without renal failure.

a. Rats with normal renal function (-/- and -/TUDC groups): the

loading dose (i.v. bolus) and constant rate i.v. infusion of CRO
were 34.8 mg/kg and 238 /ig/kg/min, respectively. b. Rats with

renal failure (UN/TUDC Group): the loading dose (i.v. bolus)
constant rate i.v. infusion of CRO were 11.7 mg/kg and 56.0
jig/kg/min,

respectively.
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Appendix A
Influence of Storage Temperature and Time
on the Protein Binding of Ceftriaxone in Serum

158

INTRODUCTION
Serum protein binding of CRO was found to be concentration

dependent. The free fraction of CRO in serum was approximately
0.07 at total concentration of 100 p,g/ml for rats with normal

kidney function and 0.244 for rats with renal failure (Table 3 in

Chapter IV). Unfortunately, the serum samples for protein binding
of CRO in our last animal study (Chapter V; TUDC studies) were
stored in a freezer which was accidently turned off. All of the

samples in storage were thawed by the time the problem was

noticed and the samples probably spent several days at room
temperature. The possible degradation of binding proteins
(albumin) and/or of CRO in these samples were therefore of

concern (it must be noted that all samples had been assayed for
total CRO concentration and TUDC level before this "accident").

When the free fraction was measured in these improperly stored

samples it was observed to be unusually high in both rats with

normal kidney function (0.314 in the -/- Group and 0.450 in the /TUDC Group) and those with renal failure (0.470 in UN/TUDC
Group)

(Table 7 in Chapter V).

A thorough search in biomedical

literature revealed no information on the impact of storage
temperature on the serum protein binding of CRO and it was highly

impractical to repeat the entire study described in Chapter V to
obtain this one parameter estimate. However, it seemed likely
that serum albumin (the binding protein of CRO) might have
degraded more readily at higher storage temperatures and that
this changed its binding behavior (caused the higher free
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fraction of this drug which was observed). Also, CRO itself might

be degraded in serum since this antibiotic is not highly stable.
The current study was designed to determine whether the free

fraction of CRO systematically increases as a function of time
when stored properly (-20°C and -70°C) and improperly (room

temperature)

(footnote a).

MATERIALS AND METHODS
Materials
Analytical grade CRO was provided by Hoffmann-La Roche
(Basel, Switzerland).
Animals

Male Sprague-Dawley rats (300-325 g) were purchased from

Harlan Sprague Dawley Inc.

(Indianapolis, IN) and maintained on a

12 hr light/dark cycle with free access to food and water.

Blank Serum Acquisition
Blank blood samples were obtained by aortic stick from 6

normal rats. Serum was separated by centrifugation and pooled.
Serum Spiking with CRO

The pooled serum was then spiked with CRO to the desired

Fortunately, all other assays (total CRO concentration,
SGPT, serum urea nitrogen, bile acids, etc.) had been
performed before this accident such that the stability of
CRO in the samples was only an issue in selecting the proper
amount of CRO to add to the sample to achieve the desired
final concentration prior to ultrafiltration (the level
of CRO in the serum samples was averaged approximately 75
pg/ml).
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concentration (-75 /Jg/ml). This concentration was selected based
upon the approximate average concentration of CRO in the three

animal groups from the last series of experiments (Chapter V).

Determination of Concentrations of Total and Free CRO
Four replicates (50 p.1) of serum spiked with CRO were
immediately analyzed by the previously established HPLC method

for the total concentration (Chapter II). The pH of serum (1 ml)
was measured and adjusted to 7.40 ± 0.05 by adding 0.5 N
orthophosphoric acid. The serum was then immediately transferred

to an ultrafiltration device (Amicon Centrifree Micropartition

System, Amicon Division, W. R. Grace & Co., Danvers, MA) and
centrifuged at 1,250 g for 10 minutes at 25°C. This procedure was

carried out in duplicate. Each filtrate was assayed twice to
determine the concentration of free CRO by using the HPLC method
described previously.
CRO Serum Sample Storage

Three equal aliquots (2.8 ml of each aliquot) of the serum
sample spiked with CRO were stored at room temperature (25°C)
after being sealed tightly. Three more aliquots were stored at

-20°C and the other three were frozen at -70°C. All aliquots were
wrapped with aluminum foil to protect samples from light. One

aliquot of the serum from each temperature condition was removed
at appropriate time intervals and thawed for the determination of
the concentrations of total and free CRO. The complete procedure

on day 0 were repeated on day 5, 10, and 20.
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RESULTS
The effect of temperature and duration of storage on the

total concentration of CRO and its free fraction is summarized in

Tables 1 and 2.
Degradation of CRO

Substantial degradation of CRO occurred when the serum

sample was stored at room temperature. The total concentration of
CRO decreased 7.8%, 15.9%, and 32.10% after five, ten, and twenty

days, respectively (Table 1). However, there was little change in
the total concentration of CRO at the storage temperatures of
-20°C and -70°C over the 20 days. Therefore, it was concluded

that the serum sample of CRO should not be left at room
temperature but stored frozen.

Protein Binding of CRO

The initial free fractions of CRO in the serum samples were
consistent with the previous data. However, when these samples

were stored at room temperature, the free fraction was increased
approximately 6-fold after 5 days and ultimately increased more

than 8-fold. There was no systematic change in the free fraction
over the same time intervals when the samples were stored at
-20°C and -70°C (Table 2).

DISCUSSION

The decreased concentration of total CRO indicated that this
drug significantly degraded over the experimental time interval
when the serum samples were stored at room temperature while
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there was no measurable degradation of CRO when the serum samples

were frozen (Table 1). The rate of degradation at room

temperature was similar over the intervals 0-5 days,

5-10 days

and 10-20 days. Because our study was intended to explain the
unexpected protein binding data discussed above and not intended

to be a formal kinetic investigation, we did not sample over a
sufficient time interval to define the "order" of this process

nor its characteristic rate constant or constants. However,

it is

clear that measurable breakdown of CRO had occurred.
Of greatest significance, the increase in free fraction

observed when the samples were stored at room temperature (Table

2) appears to explain the unusually high free fraction which was
obtained in the "TUDC Study"

(Chapter V). Again, it was

reassuring to confirm that samples frozen at -20°C and -70°C

appear to be quite stable. While the "day 20" free fraction
estimates appear to have decreased, this decrease is of modest

magnitude and it seems reasonable to tentatively attribute this

change to random error since there was no trend toward a
decreased free fraction after 5 or 10 days of storage.

Tarasidis et al. investigated the effects of storage on
valproic acid concentrations in human serum and reported that

storing samples for 4 days at room temperature did not alter the
total concentrations but was found to significantly increase the
free concentration of this drug (1). This further supports our

findings and suggests that this is not an isolated phenomenon and
might represent the general behavior of serum albumin.
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Although the breakdown of serum albumin at room temperature
was not directly studied in our experiments. It is reasonable to

suspect both the auto-degradation of albumin in rat serum as well
as the proteolysis arising from contamination with bacteria (2

3).

The degradation of rat plasma albumin has previously been

reported by Goya et al. who investigated its in vitro degradation at
37°C (2). Their experiments indicated that the range of in vitro

half-lives for rat albumin in plasma is between 3.42 to 5.25
days. Therefore,

in the present study, considerable change of CRO

protein binding at room temperature may be primarily due to the

degradation of albumin. Few data are available concerning the

extent and nature of albumin degradation by the proteolytic
bacteria which may contaminate rat serum. However, in vitro studies

by Macfarlane et al. showed that bovine serum albumin is partly
degraded in slurries of human feces over a 96 hr incubation
period and this is apparently due to the microflora (3). This may
also be possible in rat serum samples stored at room temperature.

Unfortunately, the data which we have available do not allow for
a more definitive statement regarding the causative mechanism.
In summary, the unusual high free fraction of CRO in the rat

serum samples stored at room temperature in this experiment as
well as those accidently exposed to room temperature in our

previous study (Chapter V) can probably be attributed to the
degradation of serum albumin. Therefore, it is proper to say that
protein binding of original serum samples without accidental
exposure to room temperature in our last animal study (Chapter V)
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would have had normal free fractions. Regrettably, the

consequences of TUDC and its metabolites on the free fraction of
CRO cannot be assessed and this lost data limits the
interpretation of the data in Chapter V.
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Table 1. The Effect of Temperature and Duration of Storage on the
Concentration of Total CRO in Rat Serum
Temperature

Time

Concentration of

Total CRO (jiig/ml)

Room Temperature

Day 0

75.1 ± 1.9

Day 5

69.3 ± 1.7

Day 10

63.2 ± 0.8

Day 20

-2 0°C

Day 0

75.1 ± 1.9

Day 5

75.2 ± 0.5

Day 10

75.8 ± 0.8

Day 20

-70°C

51.0 ± 0.5

74.2 ± 2.0

Day 0

75.1 ± 1.9

Day 5

76.5 ± 1.0

Day 10

74.8 ± 2.5

Day 20

77.6 ± 2.0
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Table 2. The Effect of Temperature and Duration of Storage on the
Free Fraction of CRO in Serum
Temperature

Room Temperature

Time

Free Fraction

Day 0

0.086 ± 0.003

Day 5

0.515 ± 0.001

Day 10

0.664 ± 0.002

Day 20

-20°C

-7 0°C

0.633 ± 0.002

Day 0

0.086 ± 0.003

Day 5

0.095 ± 0.005

Day 10

0.094 ± 0.003

Day 20

0.069 ± 0.001

Day 0

0.086 ± 0.003

Day 5

0.083 ± 0.004

Day 10

0.090 ± 0.003

Day 20

0.064 ± 0.001
_ . ....
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ABSTRACT
Ceftriaxone (CRO) is a third generation cephalosporin with a
long half-life. The majority of patients with severe renal
failure have slightly increased half-lives but a small subset of

patients exhibit strikingly prolonged half-lives. The reduced

ability of this minority of patients to eliminate CRO by biliary
excretion will result in excessive drug accumulation. Therefore,

the series of studies included in this dissertation were proposed
to develop a renal failure model in rats, to examined the
pharmacokinetics of CRO in this animal model, and to explore the
biliary excretion mechanisms of CRO.
Rats pretreated with uranyl nitrate exhibited a dramatic

increase of serum urea nitrogen level and a renal clearance of

total CRO approaching zero with a slightly prolonged half-life.

The biliary clearance of CRO did not change in these rats and the
protein binding of CRO was significantly reduced in uremic serum.

The rat model of renal failure appears to be satisfactory for the

study of the factors controlling the clearance/half-life of CRO
in renal failure.

The biliary excretion rate of bile acids is significantly

correlated with that of CRO in healthy humans. Therefore, the

effect of a model bile acid (tauroursodeoxycholate, TUDC) on the
biliary clearance of CRO was studied. It was observed that the
biliary clearance of total CRO decreased approximately 50% during
TUDC infusion and recovered promptly after the discontinuation of
TUDC treatment. These findings support the view that TUDC
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reversibly inhibited the biliary excretion of CRO in rats with or
without renal failure. Apparently, CRO is at least partly

excreted into bile via a transport system shared with TUDC. A

small number of rats with normal kidney function exhibited very
low biliary excretion of CRO. This might be attributable to an
inherently defective biliary transport system or accumulation of

substances which compete with this drug for this transport
system.

Overall, the findings of these studies significantly improve
the understanding of the biliary clearance of CRO.
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